[84] Bennett, D.C., How to make a melanoma: what do we know of the primary clonal

[85] Chung, C.T., et al., FISH assay development for the detection of p16/CDKN2A dele‐ tion in malignant pleural mesothelioma. J Clin Pathol, 2010. 63(7): p. 630-4.

[86] Gerami, P., et al., Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol, 2009. 33(8): p. 1146-56.

[87] Straume, O., et al., Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase.

[88] Tellez, C.S., et al., CpG island methylation profiling in human melanoma cell lines.

and reimbursement. J Natl Compr Canc Netw, 2011. 9 Suppl 6: p. S1-16.

melanoma. Mod Pathol, 2007. 20(4): p. 416-26.

tory studies. Hum Mutat, 2011. 32(8): p. 900-11.

Am J Pathol, 2002. 161(1): p. 229-37.

Melanoma Res, 2009. 19(3): p. 146-55.

events? Pigment Cell Melanoma Res, 2008. 21: p. 27-38.

tabase. Hum Mutat, 2007. 28(6): p. 622-9.

Oncogene, 1997. 15(24): p. 2991-7.

p. 835-42.

26 Melanoma - From Early Detection to Treatment

100(25): p. 14881-6.

**Chapter 2**

**Targeted Therapies in Melanoma:**

**Successes and Pitfalls**

Giuseppe Palmieri, Maria Colombino,

Amelia Lissia and Antonio Cossu

http://dx.doi.org/10.5772/53624

**1. Introduction**

Maria Cristina Sini, Paolo Antonio Ascierto,

Additional information is available at the end of the chapter

pecially dysplastic nevi, also known as atypical moles) [7-8].

Incidence of melanoma is steadily rising worldwide [1]. Lifetime risk of developing melano‐ ma in Caucasians is estimated as 1 in 50 individuals [2-3]. The incidence of melanoma varies according to the geographical origins of the population and the extent of sun exposure. In Australia and United States, an incidence of melanoma higher than observed in the Europe‐ an countries (with the notable exception of Sweden) has been reported [4-5]. There is a gra‐ dient of melanoma incidence from north to south in Europe, with highest frequencies in the northern counties. This suggests that initiation and development of melanoma is due to a combination of the damaging effects of UV and a predisposing genetic background [5].

Melanoma arises from melanocytes, neural crest-derived cells that are located in the basal layer of the epidermis and skin appendages in humans. Melanocytes, by synthesizing mela‐ nin pigments and exporting them to adjacent keratonocytes play a key role in protecting the skin from the damaging effects of ultraviolet (UV) and other solar radiation [6]. Melanocytes can proliferate to form nevi (common moles), initially in the basal epidermis (junctional ne‐ vus) and later by limited local dermal infiltration (compound nevus). Nevi develop during embryonic life (congenital nevus) and in children and adults, (acquired nevus) partly as a result of solar exposure in the latter two populations. Further progression of melanocytic tu‐ mors relates to factors that include intermittent exposure to UV radiation (though a direct relationship between risk of melanoma and UV exposure remains somehow unclear), a his‐ tory of sunburn and endogenous factors such as skin type and elevated numbers of nevi (es‐

> © 2013 Palmieri et al.; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and reproduction in any medium, provided the original work is properly cited.

© 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,

**Chapter 2**

## **Targeted Therapies in Melanoma: Successes and Pitfalls**

Giuseppe Palmieri, Maria Colombino, Maria Cristina Sini, Paolo Antonio Ascierto, Amelia Lissia and Antonio Cossu

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53624

## **1. Introduction**

Incidence of melanoma is steadily rising worldwide [1]. Lifetime risk of developing melano‐ ma in Caucasians is estimated as 1 in 50 individuals [2-3]. The incidence of melanoma varies according to the geographical origins of the population and the extent of sun exposure. In Australia and United States, an incidence of melanoma higher than observed in the Europe‐ an countries (with the notable exception of Sweden) has been reported [4-5]. There is a gra‐ dient of melanoma incidence from north to south in Europe, with highest frequencies in the northern counties. This suggests that initiation and development of melanoma is due to a combination of the damaging effects of UV and a predisposing genetic background [5].

Melanoma arises from melanocytes, neural crest-derived cells that are located in the basal layer of the epidermis and skin appendages in humans. Melanocytes, by synthesizing mela‐ nin pigments and exporting them to adjacent keratonocytes play a key role in protecting the skin from the damaging effects of ultraviolet (UV) and other solar radiation [6]. Melanocytes can proliferate to form nevi (common moles), initially in the basal epidermis (junctional ne‐ vus) and later by limited local dermal infiltration (compound nevus). Nevi develop during embryonic life (congenital nevus) and in children and adults, (acquired nevus) partly as a result of solar exposure in the latter two populations. Further progression of melanocytic tu‐ mors relates to factors that include intermittent exposure to UV radiation (though a direct relationship between risk of melanoma and UV exposure remains somehow unclear), a his‐ tory of sunburn and endogenous factors such as skin type and elevated numbers of nevi (es‐ pecially dysplastic nevi, also known as atypical moles) [7-8].

© 2013 Palmieri et al.; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Considering the growth patterns, four histological types of melanoma have been historically recognized: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nod‐ ular melanoma (NM), and acral lentiginous melanoma (ALM) [9]. Comparative genomic hy‐ bridization revealed that several genomic regions (mostly, 11q13, 22q11-13, and 5p15) were abnormally amplified in ALM [10]; such regions were different from those found altered in superficial SSM or NM (mainly, 9p21 and 1p22) [11]. Recently, a new classification of mela‐ noma including the site of primary tumour and the degree of chronic sun-induced damage of the surrounding skin has been introduced [12]. Based on these criteria, melanomas are classified into four groups; melanoma on skin with chronic sun-damage (CSD melanoma), melanoma on skin without chronic sun-damage (non-CSD melanoma), melanoma on palms, soles and nail bed (acral melanoma), and melanoma on mucous membrane (mucosal mela‐ noma) [12]. Non-CSD melanomas are characterized by high frequency of BRAF or NRAS mutations (which are mutually exclusive), while CSD, acral, and mucosal melanomas show a low frequency of BRAF/NRAS mutations but a high incidence of alterations in additional genes, such as mutations of receptor tyrosine kinase KIT gene, amplifications of cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4) genes [7, 12-13]. All genes affected into the different types of melanoma are involved in regulating cell-cycle progression and cell sur‐ vival [12-13]. On the other hand, such a difference of genetic alterations indicates distinct ge‐ netic pathways in the pathogenesis of melanoma depending on the anatomical site of the primary lesion. Trying to merge the two classifications, it could be affirmed that non-CSD melanoma roughly corresponds to SSM, CSD melanoma to LMM, and acral melanoma to ALM. Since NM may arise at any anatomical site, this histological type can not be included in any of the subgroups of the latter classification (indeed, no distinct genetic pathway has been so far correlated with NM).

During recent past years, melanocytic transformation is being demonstrated to occur as a sequential accumulation of genetic and molecular alterations [13-14]. In this sense, it is be‐ coming an unquestionable certainty that molecular classification of melanoma patients could be achieved through the assessment of the molecular profile of primary tumors and/or the correspondent metastases, by unveiling which gene or pathway is truly affect‐ ed. Although pathogenetic mechanisms underlying melanoma development are still large‐ ly unknown, several genes and metabolic pathways have been shown to carry molecular alterations in melanoma.

**Figure 1. Main pathways involved in melanomagenesis.** Arrows, activation signals. Interrupted lines, inhibition signals.

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

31

RAS proteins are small GTPases thatare activated by extracellular stimuli and regulate sig‐ nal transduction of the BRAF-MEK1/2-ERK1/2 and AKT/PI3K pathways, controlling crucial cellular processes such as proliferation, differentiation, cell adhesion, apoptosis, and cell mi‐ gration [14-16]. RAS gene is mutated in an estimated 20-30% of all cancers [17]. RAS proteins are constituted by three main isoforms - NRAS, KRAS, and HRAS, which present a similar function but a different specificity for tissue distribution [18]. On this regard, KRAS altera‐ tions mostly occur in gastrointestinal cancer [17-18], HRAS alterations are frequently ob‐ served in bladder cancer, and NRAS is mutated in 15-25% of melanomas [17-18]. Despite the huge amount of knowledge implicating RAS in tumour initiation and promotion, RAS itself

The RAF kinase family consists of three members - ARAF, BRAF, and CRAF, all of which can activate a series of protein kinases; such a signaling cascade culminate in the phosphory‐ lation and activation of the extracellular signal-regulated kinase (ERK) downstream protein [19]. In melanoma, the most commonly mutated component of this pathway is the *BRAF* gene; the prevalent *BRAF* mutation (in nearly, 90% of cases) being a substitution of valine with glutamic acid at position 600 (V600E) [20]. Mutated *BRAF* induces constitutive ERK ac‐ tivation; activated ERK then translocates to the nucleus and initiates the transcription of a variety of growth-related genes, stimulating cell proliferation and survival [20]. Indeed, the

has not become a successful target of therapy.

## **2. Main genes and related pathways**

#### **2.1.** *BRAF* **and MAPK pathway**

The *mitogen-activated protein kinase* (MAPK) signal transduction pathway regulates cell growth, survival, and invasion. MAPK signaling is initiated at the cell membrane, either by receptor tyrosine kinases (RTKs) binding ligand or integrin adhesion to extracellular matrix, which transmits activation signals via RAS on the cell membrane inner surface (Figure 1).

Considering the growth patterns, four histological types of melanoma have been historically recognized: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nod‐ ular melanoma (NM), and acral lentiginous melanoma (ALM) [9]. Comparative genomic hy‐ bridization revealed that several genomic regions (mostly, 11q13, 22q11-13, and 5p15) were abnormally amplified in ALM [10]; such regions were different from those found altered in superficial SSM or NM (mainly, 9p21 and 1p22) [11]. Recently, a new classification of mela‐ noma including the site of primary tumour and the degree of chronic sun-induced damage of the surrounding skin has been introduced [12]. Based on these criteria, melanomas are classified into four groups; melanoma on skin with chronic sun-damage (CSD melanoma), melanoma on skin without chronic sun-damage (non-CSD melanoma), melanoma on palms, soles and nail bed (acral melanoma), and melanoma on mucous membrane (mucosal mela‐ noma) [12]. Non-CSD melanomas are characterized by high frequency of BRAF or NRAS mutations (which are mutually exclusive), while CSD, acral, and mucosal melanomas show a low frequency of BRAF/NRAS mutations but a high incidence of alterations in additional genes, such as mutations of receptor tyrosine kinase KIT gene, amplifications of cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4) genes [7, 12-13]. All genes affected into the different types of melanoma are involved in regulating cell-cycle progression and cell sur‐ vival [12-13]. On the other hand, such a difference of genetic alterations indicates distinct ge‐ netic pathways in the pathogenesis of melanoma depending on the anatomical site of the primary lesion. Trying to merge the two classifications, it could be affirmed that non-CSD melanoma roughly corresponds to SSM, CSD melanoma to LMM, and acral melanoma to ALM. Since NM may arise at any anatomical site, this histological type can not be included in any of the subgroups of the latter classification (indeed, no distinct genetic pathway has

During recent past years, melanocytic transformation is being demonstrated to occur as a sequential accumulation of genetic and molecular alterations [13-14]. In this sense, it is be‐ coming an unquestionable certainty that molecular classification of melanoma patients could be achieved through the assessment of the molecular profile of primary tumors and/or the correspondent metastases, by unveiling which gene or pathway is truly affect‐ ed. Although pathogenetic mechanisms underlying melanoma development are still large‐ ly unknown, several genes and metabolic pathways have been shown to carry molecular

The *mitogen-activated protein kinase* (MAPK) signal transduction pathway regulates cell growth, survival, and invasion. MAPK signaling is initiated at the cell membrane, either by receptor tyrosine kinases (RTKs) binding ligand or integrin adhesion to extracellular matrix, which transmits activation signals via RAS on the cell membrane inner surface (Figure 1).

been so far correlated with NM).

30 Melanoma - From Early Detection to Treatment

alterations in melanoma.

**2.1.** *BRAF* **and MAPK pathway**

**2. Main genes and related pathways**

**Figure 1. Main pathways involved in melanomagenesis.** Arrows, activation signals. Interrupted lines, inhibition signals.

RAS proteins are small GTPases thatare activated by extracellular stimuli and regulate sig‐ nal transduction of the BRAF-MEK1/2-ERK1/2 and AKT/PI3K pathways, controlling crucial cellular processes such as proliferation, differentiation, cell adhesion, apoptosis, and cell mi‐ gration [14-16]. RAS gene is mutated in an estimated 20-30% of all cancers [17]. RAS proteins are constituted by three main isoforms - NRAS, KRAS, and HRAS, which present a similar function but a different specificity for tissue distribution [18]. On this regard, KRAS altera‐ tions mostly occur in gastrointestinal cancer [17-18], HRAS alterations are frequently ob‐ served in bladder cancer, and NRAS is mutated in 15-25% of melanomas [17-18]. Despite the huge amount of knowledge implicating RAS in tumour initiation and promotion, RAS itself has not become a successful target of therapy.

The RAF kinase family consists of three members - ARAF, BRAF, and CRAF, all of which can activate a series of protein kinases; such a signaling cascade culminate in the phosphory‐ lation and activation of the extracellular signal-regulated kinase (ERK) downstream protein [19]. In melanoma, the most commonly mutated component of this pathway is the *BRAF* gene; the prevalent *BRAF* mutation (in nearly, 90% of cases) being a substitution of valine with glutamic acid at position 600 (V600E) [20]. Mutated *BRAF* induces constitutive ERK ac‐ tivation; activated ERK then translocates to the nucleus and initiates the transcription of a variety of growth-related genes, stimulating cell proliferation and survival [20]. Indeed, the increased activity of ERK seems to be implicated in rapid melanoma cell growth, enhanced cell survival and resistance to apoptosis [21]. High levels of activated ERK may further in‐ duce the metastatic potential of melanoma by increasing the expression of invasion-promot‐ ing integrins [22-23]. Presence of *BRAF* mutations in benign and dysplastic nevi supports the hypothesis that activation of the RAF/MEK/ERK pathway is an early event in melanoma progression [24-25]. In other words, *BRAF* activation is necessary but not sufficient for the development of melanoma and additional co-operating genetic events are required to ach‐ ieve full malignancy.

cyclin/CDK complexes and, in this way, ensuring the control of the cell replication [33]. In particular, p16CDKN2A is part of the G1–S cell cycle checkpoint mechanism that involves the retinoblastoma-susceptibility tumor suppressor protein (pRb). The p16CDKN2A inhibits the Cyclin D/CDK4 complex, which, in turn, phosphorylates pRb and allows progression through the G1–S checkpoint (Figure 1) [33]. The *Cyclin D* (*CCND1*) and *CDK4* genes are found altered in less than 5% of total melanomas [12], though with an heterogeneous prevalence according to the distinct types of melanoma (see above). Somatic *CDK4* ampli‐ fication is relatively common in acral and mucosal melanomas [12], whereas germline *CDK4* mutations are observed in a limited fraction of melanoma-prone families [34]. The *CCND1* gene amplifications is primarily found in ALM lesions (more than one third of cases) and to a lesser degree in other types (11% for LMM and 6% for SSM) [35]. Regard‐ ing the alternative *CDKN2A* gene product, p14CDKN2A is an antagonist of the murine dou‐ ble minute 2 (MDM2) protein, which targets p53 to degradation by ubiquitination and proteasome processing, thus abrogating p53 control of cell growth (Figure 1) [32-33]. In particular, the p14CDKN2A protein exerts a tumor suppressor effect by inhibiting the onco‐ genic actions of the downstream MDM2 protein, whose direct interaction with p53 blocks any p53-mediated activity and targets the p53 protein for rapid degradation [32-33]. The p53 is a transcription factor that functions as a major negative regulator of cell prolifera‐ tion and survival, being activated by different adverse signals (i.e. growth factors with‐ drawal, DNA damage, oncogenic aberrations, hypoxia, etc.) and driving cells to either interrupt progression into the cell-cycle or enter apoptosis program, in order to avoid re‐ production of altered cells [33, 36]. In normal conditions, expression levels of p53 within cells are low. In response to DNA damage, p53 accumulates and prevents cell division. Therefore, inactivation of the *TP53* gene results in an intracellular accumulation of genetic damage which promotes tumor formation [36]. In melanoma, such an inactivation is most‐ ly due to functional gene silencing since the frequency of *TP53* mutations is low (less than 10% of cases) [37]. Impairment of the p14CDKN2A-MDM2-p53 cascade, whose final effectors are the Bax/Bcl-2 proteins, has been implicated in defective apoptotic responses to geno‐ toxic damage and, thus, to anticancer agents (in most cases, high expression levels of Bcl-2 protein have been demonstrated to reduce apoptosis and sensitivity of melanoma cells to proapoptotic stimuli, contributing to further increase tumor aggressiveness and refractori‐

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

33

More in general, genetic loss or rearrangement in the CDKN2A locus may result in im‐ pairing or silencing p16CDKN2A, p14CDKN2A or both genes, with the consequence of losing the mechanisms controlling cell proliferation and/or survival. In melanoma, the *CDKN2A* gene is somatically inactivated by genomic deletions (approximately 50% of cases) or point mutations (about 10% of cases); in addition, this gene is often transcriptionally si‐ lenced by promoter hypermethylation [38]. A reduced expression of the p16CDKN2A protein seems to be strictly associated with malignant tumor invasion, varying from 5% to about 15% in benign melanocytic lesions, from 10% to about 50% in primary melanomas, and from 50% to about 60% in melanoma metastases [39]. The *CDKN2A* gene is frequently mutated at germline level in patients with a strong familial history of melanoma (three or more affected family members), indicating that it represents a key susceptibility gene for

ness to therapy) [33].

In a study aimed to better define the role of BRAF in melanomagenesis, a transgenic zebra fish expressing V600EBRAF showed dramatic development of patches of ectopic melanocytes (designated as fish-nevi) [26]. Remarkably, activated *BRAF* in p53-deficient zebra fish in‐ duced the formation of melanocytic lesions that rapidly developed into invasive melanomas that resembled human melanomas in terms of their histology and biological behaviors [26]. These data provide direct evidence that the p53 and BRAF pathways interact functionally during melanomagenesis.

The *BRAF* gene also cooperates with the cyclin-dependent kinase inhibitor p16CDKN2A (see be‐ low). Activating *BRAF* mutations have been reported to constitutively induce up-regulation of *p16*CDKN2A and cell cycle arrest (this phenomenon appears to be a protective response to an inappropriate mitogenic signal). In particular, mutant BRAF protein induces cell senescence by increasing the expression levels of the p16CDKN2A protein, which, in turn, may limit hyper‐ plastic growth caused by *BRAF* mutations [25]. Therefore, inactivation of *p16*CDKN2A gene may promote the melanocytic proliferation depending on oncogenic *BRAF*. In this sense, several factors seem to be able to induce the arrest of the cell cycle and cell senescence caused by *BRAF* activation [27-28].

Finally, it has been showed that primary melanomas arising from chronically sun-damages skin and from mucosal sites, which typically do not harbour *BRAF* and *NRAS* mutations, have increased copy number of the *CCND1/Cyclin D1* gene [12]. In contrast to primary mela‐ nomas, a subset (>15%) of metastatic melanoma samples with *BRAF* mutations also exhibit amplification of *CCND1/Cyclin D1*. These melanomas are resistant to BRAF inhibitors high‐ lighting the need for combination therapy [29-30].

#### **2.2.** *CDKN2A* **and senescence/apoptosis pathways**

The cyclin-dependent kinase inhibitor 2 (*CDKN2A*; at chromosome 9p21) gene encodes two proteins, p16CDKN2A and p14CDKN2A (a product of an alternative splicing), that are known to function as tumor suppressors [31-33]. The cyclin proteins are regulatory effec‐ tors able to bind and activate the cyclin-dependent kinases (CDKs) that bear catalytic kin‐ ase activity. Several distinct cyclin/CDK complexes have been identified and functionally assigned to specific phases of the cell cycle: Cyclin D/CDK4 complex leads the passage from the pre-replicative (G1) to the DNA duplication (S) phase; the Cyclin E/CDK2 com‐ plex promotes the progression through the S phase and the Cyclin B/CDK1 complex indu‐ ces cells to enter mitosis [31-32]. In such a functional network, proteins like p16CDKN2A and p14CDKN2A act as inhibitors of the cell cycle, negatively interfering with the activity of the cyclin/CDK complexes and, in this way, ensuring the control of the cell replication [33]. In particular, p16CDKN2A is part of the G1–S cell cycle checkpoint mechanism that involves the retinoblastoma-susceptibility tumor suppressor protein (pRb). The p16CDKN2A inhibits the Cyclin D/CDK4 complex, which, in turn, phosphorylates pRb and allows progression through the G1–S checkpoint (Figure 1) [33]. The *Cyclin D* (*CCND1*) and *CDK4* genes are found altered in less than 5% of total melanomas [12], though with an heterogeneous prevalence according to the distinct types of melanoma (see above). Somatic *CDK4* ampli‐ fication is relatively common in acral and mucosal melanomas [12], whereas germline *CDK4* mutations are observed in a limited fraction of melanoma-prone families [34]. The *CCND1* gene amplifications is primarily found in ALM lesions (more than one third of cases) and to a lesser degree in other types (11% for LMM and 6% for SSM) [35]. Regard‐ ing the alternative *CDKN2A* gene product, p14CDKN2A is an antagonist of the murine dou‐ ble minute 2 (MDM2) protein, which targets p53 to degradation by ubiquitination and proteasome processing, thus abrogating p53 control of cell growth (Figure 1) [32-33]. In particular, the p14CDKN2A protein exerts a tumor suppressor effect by inhibiting the onco‐ genic actions of the downstream MDM2 protein, whose direct interaction with p53 blocks any p53-mediated activity and targets the p53 protein for rapid degradation [32-33]. The p53 is a transcription factor that functions as a major negative regulator of cell prolifera‐ tion and survival, being activated by different adverse signals (i.e. growth factors with‐ drawal, DNA damage, oncogenic aberrations, hypoxia, etc.) and driving cells to either interrupt progression into the cell-cycle or enter apoptosis program, in order to avoid re‐ production of altered cells [33, 36]. In normal conditions, expression levels of p53 within cells are low. In response to DNA damage, p53 accumulates and prevents cell division. Therefore, inactivation of the *TP53* gene results in an intracellular accumulation of genetic damage which promotes tumor formation [36]. In melanoma, such an inactivation is most‐ ly due to functional gene silencing since the frequency of *TP53* mutations is low (less than 10% of cases) [37]. Impairment of the p14CDKN2A-MDM2-p53 cascade, whose final effectors are the Bax/Bcl-2 proteins, has been implicated in defective apoptotic responses to geno‐ toxic damage and, thus, to anticancer agents (in most cases, high expression levels of Bcl-2 protein have been demonstrated to reduce apoptosis and sensitivity of melanoma cells to proapoptotic stimuli, contributing to further increase tumor aggressiveness and refractori‐ ness to therapy) [33].

increased activity of ERK seems to be implicated in rapid melanoma cell growth, enhanced cell survival and resistance to apoptosis [21]. High levels of activated ERK may further in‐ duce the metastatic potential of melanoma by increasing the expression of invasion-promot‐ ing integrins [22-23]. Presence of *BRAF* mutations in benign and dysplastic nevi supports the hypothesis that activation of the RAF/MEK/ERK pathway is an early event in melanoma progression [24-25]. In other words, *BRAF* activation is necessary but not sufficient for the development of melanoma and additional co-operating genetic events are required to ach‐

In a study aimed to better define the role of BRAF in melanomagenesis, a transgenic zebra fish expressing V600EBRAF showed dramatic development of patches of ectopic melanocytes (designated as fish-nevi) [26]. Remarkably, activated *BRAF* in p53-deficient zebra fish in‐ duced the formation of melanocytic lesions that rapidly developed into invasive melanomas that resembled human melanomas in terms of their histology and biological behaviors [26]. These data provide direct evidence that the p53 and BRAF pathways interact functionally

The *BRAF* gene also cooperates with the cyclin-dependent kinase inhibitor p16CDKN2A (see be‐ low). Activating *BRAF* mutations have been reported to constitutively induce up-regulation of *p16*CDKN2A and cell cycle arrest (this phenomenon appears to be a protective response to an inappropriate mitogenic signal). In particular, mutant BRAF protein induces cell senescence by increasing the expression levels of the p16CDKN2A protein, which, in turn, may limit hyper‐ plastic growth caused by *BRAF* mutations [25]. Therefore, inactivation of *p16*CDKN2A gene may promote the melanocytic proliferation depending on oncogenic *BRAF*. In this sense, several factors seem to be able to induce the arrest of the cell cycle and cell senescence

Finally, it has been showed that primary melanomas arising from chronically sun-damages skin and from mucosal sites, which typically do not harbour *BRAF* and *NRAS* mutations, have increased copy number of the *CCND1/Cyclin D1* gene [12]. In contrast to primary mela‐ nomas, a subset (>15%) of metastatic melanoma samples with *BRAF* mutations also exhibit amplification of *CCND1/Cyclin D1*. These melanomas are resistant to BRAF inhibitors high‐

The cyclin-dependent kinase inhibitor 2 (*CDKN2A*; at chromosome 9p21) gene encodes two proteins, p16CDKN2A and p14CDKN2A (a product of an alternative splicing), that are known to function as tumor suppressors [31-33]. The cyclin proteins are regulatory effec‐ tors able to bind and activate the cyclin-dependent kinases (CDKs) that bear catalytic kin‐ ase activity. Several distinct cyclin/CDK complexes have been identified and functionally assigned to specific phases of the cell cycle: Cyclin D/CDK4 complex leads the passage from the pre-replicative (G1) to the DNA duplication (S) phase; the Cyclin E/CDK2 com‐ plex promotes the progression through the S phase and the Cyclin B/CDK1 complex indu‐ ces cells to enter mitosis [31-32]. In such a functional network, proteins like p16CDKN2A and p14CDKN2A act as inhibitors of the cell cycle, negatively interfering with the activity of the

ieve full malignancy.

32 Melanoma - From Early Detection to Treatment

during melanomagenesis.

caused by *BRAF* activation [27-28].

lighting the need for combination therapy [29-30].

**2.2.** *CDKN2A* **and senescence/apoptosis pathways**

More in general, genetic loss or rearrangement in the CDKN2A locus may result in im‐ pairing or silencing p16CDKN2A, p14CDKN2A or both genes, with the consequence of losing the mechanisms controlling cell proliferation and/or survival. In melanoma, the *CDKN2A* gene is somatically inactivated by genomic deletions (approximately 50% of cases) or point mutations (about 10% of cases); in addition, this gene is often transcriptionally si‐ lenced by promoter hypermethylation [38]. A reduced expression of the p16CDKN2A protein seems to be strictly associated with malignant tumor invasion, varying from 5% to about 15% in benign melanocytic lesions, from 10% to about 50% in primary melanomas, and from 50% to about 60% in melanoma metastases [39]. The *CDKN2A* gene is frequently mutated at germline level in patients with a strong familial history of melanoma (three or more affected family members), indicating that it represents a key susceptibility gene for familial melanoma [40]. In melanoma, CDKN2A mutations typically occur in the p16CDKN2A gene, either alone or in combination with p14CDKN2A gene (some families harbor however mutations only in this latter gene) [33, 40].

unable to stimulate phosphorylation of the PI3K protein; this in turn maintains suppression of cell cycle progression and cell growth. In other words, there is a balance between PIP2 and PIP3 which is maintained by the opposite activities of PTEN and PI3K, which instead converts PIP2 into PIP3 [50]. Upon growth stimulation, mainly obtained by triggering the RAS kinase, PI3K is constitutively activated (Figure 1), resulting in an increase of intracellu‐ lar levels of PIP3 and a consequent activation of AKT by phosphorylation [50-51]. Activated AKT in turn phosphorylates its substrate, the serine/threonine kinase mTOR, leading to in‐ creased synthesis of target proteins that promote cell division and survival as well as apop‐ totic escape [51]. The mechanisms associated with the ability of AKT to suppress apoptosis include the phosphorylation and inactivation of many pro-apoptotic proteins, such as BAD (Bcl-2 antagonist of cell death) and MDM2, as well as the activation of NF-kB [52] (Figure 1). Three *AKT* genes have been described in humans: *AKT1*, which is involved in apoptosis and protein synthesis; *AKT2*, which is involved in controlling the glucose metabolism; and *AKT3*, whose increased activity (often associated with the amplification of the *AKT3* locus at chromosome 1q43-44) is mainly involved in stimulating cell growth and has been implicated in many cancers including melanoma [51-52]. More than two thirds of primary and meta‐ static melanomas exhibit higher levels of phosphorylated AKT [52], suggesting that such an

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

35

alteration might be considered as an early event in melanoma pathogenesis.

sion of phosphorylated AKT [37].

spreading and migration [33, 50].

**2.4.** *MITF* **and melanocytic differentiation**

Overall, PI3K expression is higher in malignant melanomas, as compared to nevi, and seems to correlate with a worse prognosis [53]. In primary melanomas, since activating mutations of PI3K are quite rare (about 1%)*,* and comparative genomic hybridization did not reveal amplification at this gene locus [12, 37], activation of the PI3K pathway is most‐ ly due to functional silencing of the tumour suppressor gene PTEN. Inactivation of *PTEN* gene is mainly due to hypermethylation-based epigenetic mechanisms, with a low inci‐ dence (less than 10%) of somatic mutations and/or allelic deletions; loss of (or reduced) PTEN protein is observed by immunohistochemistry in 20-40% of melanoma tissues [54-55]. Consistent with its role in the PI3K-AKT pathway, vast majority (more than 80%) of melanoma samples with loss of PTEN protein presents a significant increase in expres‐

*PTEN* inactivation has been mostly observed as a late event in melanoma, although a dosedependent down-regulation of PTEN expression has been implicated in early stages of tu‐ morigenesis, often occurring in conjunction with mutations in *BRAF* gene (which have been demonstrated to indeed play a role in induction of the melanocytic proliferation and early steps of melanoma development) [50]. PTEN downregulation In addition, alterations of the BRAF-MAPK pathway are frequently associated with PTEN-AKT impairment [7, 56]. In summary, the combined effects of the inactivation of *PTEN* gene and activation of the PI3K-AKT effectors may result in aberrant cell growth, apoptosis escape, and abnormal cell

The microphthalmia-associated transcription factor (MITF) is a transcription factor that is in‐ volved in differentiation and maintenance of melanocytes, playing a role in melanoma de‐

A recent meta-analysis of studies conducted in independent populations indicated that mul‐ tiple variants of the melanocortin-1 receptor (*MC1R*) gene increase the melanoma risk in *CDKN2A* mutation carriers [41]. The *MC1R* gene encodes a G-protein coupled receptor. In the skin, two types of melanin pigment, dark-protective eumelanin and red-photo reactive pheomelanin, are present [42]. MC1R plays an important role in determining the ratio of eu‐ melanin and pheomelanin production. After stimulation by UV, keratinocytes produce al‐ pha melanocyte stimulating hormone (MSH) that binds to the MC1R on melanocytes and shifts the balance of these two pigments in the direction of eumelanin [42]. In particular, stimulation of MC1R by MSH mediates activation of adenylate cyclase, subsequent eleva‐ tion of cAMP levels, and activation of the microphthalmia transcription factor (MITF; see be‐ low). Activated MITF binds to a conserved region found in the promoters of the *tyrosinase* (*TYR*), *tyrosinase-related protein 1* (*TYRP1*), and *DOPAchrome tautomerase* (*DCT*) genes, stimu‐ lating the transcriptional up-regulation of these proteins and inducing maturation of the melanosomes [43]. This ultimately results in increased eumelanin production and darkening of the skin or hair.

New findings have shed light on the mechanisms by which MC1R contributes to melanoma risk. In vitro studies showed that acute UV irradiation of melanocytes with impaired MC1R results in an increased production of free radicals [44]. Melanomas that arise on body sites only intermittently exposed to sun, and which therefore lack marked signs of chronic solar damage, were found to have a high frequency of *BRAF* mutations [12]. One could speculate that induction of *BRAF* mutations may occur only when solar exposure is not sufficiently prolonged to induce the striking tissue changes that generate the hallmark signs of solar damage. Several *MC1R* variants, that impairing relevant protein function, have been associ‐ ated with *BRAF* mutation in melanoma arising in Caucasian populations from United States and Europe [45-48]. On the basis of such indications, it is possible that increased production of free radicals following UV exposure is combination with impairment of *MC1R* may in‐ duce mutations in the *BRAF* gene.

Additional mechanisms promoting susceptibility to pathogenetic mutations of the *BRAF* gene may however exist since there is no demonstrable association between germ line *MC1R* status and the prevalence of somatic *BRAF* mutations in melanomas from Australian popu‐ lation, even after classifying the melanomas by their location relative to intermittent and chronic sun-exposure [49].

#### **2.3.** *PTEN* **and mTORC pathways**

Phosphatase and tensin homolog deleted in chromosome ten (PTEN) has a key role in cellu‐ lar signal transduction by decreasing intracellular phosphatidylinositol [3,4-bisphosphate (PIP2) and 3,4,5-triphosphate (PIP3)] that are produced by the activation of phoshoinosite 3 kinase (PI3K) [50]. In the absence of extracellular growth stimuli mediated by cell surface re‐ ceptors and G-proteins, PTEN dephosphorylates PIP3 generating the PIP2 phospholipid, unable to stimulate phosphorylation of the PI3K protein; this in turn maintains suppression of cell cycle progression and cell growth. In other words, there is a balance between PIP2 and PIP3 which is maintained by the opposite activities of PTEN and PI3K, which instead converts PIP2 into PIP3 [50]. Upon growth stimulation, mainly obtained by triggering the RAS kinase, PI3K is constitutively activated (Figure 1), resulting in an increase of intracellu‐ lar levels of PIP3 and a consequent activation of AKT by phosphorylation [50-51]. Activated AKT in turn phosphorylates its substrate, the serine/threonine kinase mTOR, leading to in‐ creased synthesis of target proteins that promote cell division and survival as well as apop‐ totic escape [51]. The mechanisms associated with the ability of AKT to suppress apoptosis include the phosphorylation and inactivation of many pro-apoptotic proteins, such as BAD (Bcl-2 antagonist of cell death) and MDM2, as well as the activation of NF-kB [52] (Figure 1).

Three *AKT* genes have been described in humans: *AKT1*, which is involved in apoptosis and protein synthesis; *AKT2*, which is involved in controlling the glucose metabolism; and *AKT3*, whose increased activity (often associated with the amplification of the *AKT3* locus at chromosome 1q43-44) is mainly involved in stimulating cell growth and has been implicated in many cancers including melanoma [51-52]. More than two thirds of primary and meta‐ static melanomas exhibit higher levels of phosphorylated AKT [52], suggesting that such an alteration might be considered as an early event in melanoma pathogenesis.

Overall, PI3K expression is higher in malignant melanomas, as compared to nevi, and seems to correlate with a worse prognosis [53]. In primary melanomas, since activating mutations of PI3K are quite rare (about 1%)*,* and comparative genomic hybridization did not reveal amplification at this gene locus [12, 37], activation of the PI3K pathway is most‐ ly due to functional silencing of the tumour suppressor gene PTEN. Inactivation of *PTEN* gene is mainly due to hypermethylation-based epigenetic mechanisms, with a low inci‐ dence (less than 10%) of somatic mutations and/or allelic deletions; loss of (or reduced) PTEN protein is observed by immunohistochemistry in 20-40% of melanoma tissues [54-55]. Consistent with its role in the PI3K-AKT pathway, vast majority (more than 80%) of melanoma samples with loss of PTEN protein presents a significant increase in expres‐ sion of phosphorylated AKT [37].

*PTEN* inactivation has been mostly observed as a late event in melanoma, although a dosedependent down-regulation of PTEN expression has been implicated in early stages of tu‐ morigenesis, often occurring in conjunction with mutations in *BRAF* gene (which have been demonstrated to indeed play a role in induction of the melanocytic proliferation and early steps of melanoma development) [50]. PTEN downregulation In addition, alterations of the BRAF-MAPK pathway are frequently associated with PTEN-AKT impairment [7, 56]. In summary, the combined effects of the inactivation of *PTEN* gene and activation of the PI3K-AKT effectors may result in aberrant cell growth, apoptosis escape, and abnormal cell spreading and migration [33, 50].

#### **2.4.** *MITF* **and melanocytic differentiation**

familial melanoma [40]. In melanoma, CDKN2A mutations typically occur in the p16CDKN2A gene, either alone or in combination with p14CDKN2A gene (some families harbor however

A recent meta-analysis of studies conducted in independent populations indicated that mul‐ tiple variants of the melanocortin-1 receptor (*MC1R*) gene increase the melanoma risk in *CDKN2A* mutation carriers [41]. The *MC1R* gene encodes a G-protein coupled receptor. In the skin, two types of melanin pigment, dark-protective eumelanin and red-photo reactive pheomelanin, are present [42]. MC1R plays an important role in determining the ratio of eu‐ melanin and pheomelanin production. After stimulation by UV, keratinocytes produce al‐ pha melanocyte stimulating hormone (MSH) that binds to the MC1R on melanocytes and shifts the balance of these two pigments in the direction of eumelanin [42]. In particular, stimulation of MC1R by MSH mediates activation of adenylate cyclase, subsequent eleva‐ tion of cAMP levels, and activation of the microphthalmia transcription factor (MITF; see be‐ low). Activated MITF binds to a conserved region found in the promoters of the *tyrosinase* (*TYR*), *tyrosinase-related protein 1* (*TYRP1*), and *DOPAchrome tautomerase* (*DCT*) genes, stimu‐ lating the transcriptional up-regulation of these proteins and inducing maturation of the melanosomes [43]. This ultimately results in increased eumelanin production and darkening

New findings have shed light on the mechanisms by which MC1R contributes to melanoma risk. In vitro studies showed that acute UV irradiation of melanocytes with impaired MC1R results in an increased production of free radicals [44]. Melanomas that arise on body sites only intermittently exposed to sun, and which therefore lack marked signs of chronic solar damage, were found to have a high frequency of *BRAF* mutations [12]. One could speculate that induction of *BRAF* mutations may occur only when solar exposure is not sufficiently prolonged to induce the striking tissue changes that generate the hallmark signs of solar damage. Several *MC1R* variants, that impairing relevant protein function, have been associ‐ ated with *BRAF* mutation in melanoma arising in Caucasian populations from United States and Europe [45-48]. On the basis of such indications, it is possible that increased production of free radicals following UV exposure is combination with impairment of *MC1R* may in‐

Additional mechanisms promoting susceptibility to pathogenetic mutations of the *BRAF* gene may however exist since there is no demonstrable association between germ line *MC1R* status and the prevalence of somatic *BRAF* mutations in melanomas from Australian popu‐ lation, even after classifying the melanomas by their location relative to intermittent and

Phosphatase and tensin homolog deleted in chromosome ten (PTEN) has a key role in cellu‐ lar signal transduction by decreasing intracellular phosphatidylinositol [3,4-bisphosphate (PIP2) and 3,4,5-triphosphate (PIP3)] that are produced by the activation of phoshoinosite 3 kinase (PI3K) [50]. In the absence of extracellular growth stimuli mediated by cell surface re‐ ceptors and G-proteins, PTEN dephosphorylates PIP3 generating the PIP2 phospholipid,

mutations only in this latter gene) [33, 40].

34 Melanoma - From Early Detection to Treatment

of the skin or hair.

duce mutations in the *BRAF* gene.

**2.3.** *PTEN* **and mTORC pathways**

chronic sun-exposure [49].

The microphthalmia-associated transcription factor (MITF) is a transcription factor that is in‐ volved in differentiation and maintenance of melanocytes, playing a role in melanoma de‐ velopment and pathogenesis [43, 57]. MITF is activated by the MAPK pathway as well as by the cAMP pathway (Figure 1), and leads to transcription of genes involved in pigmentation (TYR, TYRP1, and DCT; see above) as well as cell cycle progression and survival [43]. The *MITF* gene is amplified in melanoma (about 20% of cases); *MITF* amplification correlated with increased resistance to chemotherapy and decreased overall survival [57].

cytoplasm. NF-κB exists as cytoplasmic hetero- or homodimers associated with members of the inhibitor-of-kB (IkB) proteins (IkB*a*, Ik*Bb* and IkB*e*), which form complexes seques‐ tering NF-kB into the cytoplasm [74]. Upon appropriate stimulation, the phosphorylation of IkB proteins is promoted, triggering their ubiquitination and degradation in the protea‐ some [74]. As a consequence, NF-kB may translocate to the nucleus where it binds to tar‐ get DNA loci and induces transcription of several genes - including *iNOS* - associated with immune and inflammatory response, angiogenesis, cell proliferation, tumor promo‐

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

37

Regarding the role of NF-kB in tumorigenesis, there are compelling evidence that activation of NF-kB controls multiple cellular processes in cancer due to its ability to promote cell pro‐ liferation, suppress apoptosis, promote cell migration, and suppress cell differentiation, opening the way for new therapeutic approaches against such a target [75-76]. In melanoma, NF-kB is constitutively activated since expression of the IkB proteins seems to be significant‐

cKIT is a member of the transmenbrane receptor tyrosine kinase family that comprised five immunoglobin-like motifs, a single transmembrane region, an inhibitory cytoplasmic juxta‐ menbrane domain, and a split cytoplasmic kinase domain separated by a kinase insert seg‐ ment [78]. Under physiological conditions, binding of the cKIT ligand stem-cell factor (SCF) to the extracellular domain of the receptor leads its dimerization, activation of the intracellu‐ lar tyrosine kinase domain through autophosporylation of specific tyrosine residue [78]. The intracellular signaling through cKIT plays a critical role in the development of several mam‐ malian cells, including growth, differentiation, migration, and proliferation of melanocytes [79]. It has been defined that cKIT recruits and activates a number of intracellular signaling pathways implicated in tumor progression, such as MAPK, PI3K/AKT, Src, activators of

Although the role of cKIT in melanomagenesis is still controversial, several studies have reported its downregulation during melanoma growth and invasion (in vertical growth phase of melanoma and metastatic lesions) [81-83]. Indeed, the majority of highly meta‐ static human melanomas do not express detectable levels of the cKIT receptor [83]. As a confirmation of this, over-expression of cKIT in metastatic melanoma cell lines led to im‐ portant reduction in tumor growth, while cKIT activation through exposure to cKIT li‐

Specific mutations within the cKIT gene cause constitutive phosphorylation and activation of the kinase domain resulting in uncontrolled cell proliferation. [84]. Although such muta‐ tions seem to be more rare than *BRAF* and *NRAS* mutations, these may reflect the important role of cKIT tyrosine kinase in melanocyte development [84]. Sequencing of cKIT exons 11, 13, 17, and 18 revealed the most prevalent mutation to be K642, L576P, D816H-V, V559A [84]. The cKIT mutations are more common in mucosal and acral melanomas compared with cutaneous melanomas and are in most cases accompanied by an increase in gene copy number (40% mucosal or acral melanomas - frequently, associated with amplification of *cy‐*

tion, and apoptosis [73-74].

ly reduced in comparison to nevi [77].

gands induced apoptosis [83].

**2.6.** *cKIT* **and tyrosinase kinase receptors**

transcription (STAT), and phospholipase-C (PLC) [79-80].

The connection between MITF and melanoma development is complex because it plays a double role of inducer/repressor of cellular proliferation. High levels of MITF expression lead to G1 cell-cycle arrest and differentiation, through induction of the cell cycle inhibitors p16CDKN2A and p21 [58-59] (Figure 1). Very low or null MITF expression levels predispose to apoptosis whereas inter-mediate MITF expression levels promote cell proliferation [57-59]. Therefore, it is thought that melanoma cells have developed strategies to maintain MITF lev‐ els in the range compatible with tumorigenesis. It has been shown that constitutive ERK ac‐ tivity, stimulated by V600EBRAF in melanoma cells, is associated with MITF ubiquitindependent degradation [60]. Nevertheless, continued expression of MITF is necessary for proliferation and survival of melanoma cells, because it also regulates CDK2 and Bcl-2 genes [61-62]. It has been recently shown that oncogenic BRAF may control intracellular levels of the MITF protein through a fine balance of two opposite mechanisms: a direct reduction of MITF levels, by inducing protein degradation, and an indirect increase of MITF levels, by stimulating transcription factors which increase protein expression levels [63]. Oncogenic *BRAF* mutations are associated with *MITF* amplification in a low fraction (10-15%) of mela‐ nomas [63], suggesting that other mechanisms are likely to be involved in ERK-dependent degradation of MITF.

#### **2.5.** *iNOS* **and** *NF-kB* **pathways**

Human melanoma cells are known to express the inducible nitric oxide synthase (iNOS) enzyme, which is responsible for synthesis of nitric oxide (NO), a free radical involved in several physiological processes such as neurotransmission, vasodilation, and regulation of immune responses [64]. The iNOS enzyme has been found to be frequently expressed in melanoma [65-66] and the subsequent increased concentrations of NO have been demon‐ strated to contribute to melanomagenesis through a sustained protection of the tumour from apoptosis [67]. However, the role of iNOS in melanoma progression remains contro‐ versial. Higher levels of iNOS have been found in subcutaneous and lymph node metasta‐ ses of non-progressive melanoma as compared to metastases of progressive melanoma [68], however, iNOS was found to be expressed to a lesser extent in metastases as com‐ pared with nevi and primary melanomas [69]. Nevertheless, the expression of iNOS in pa‐ tients with lymph nodes and in-transit metastases (stage III disease) has been proposed as an indicator of poor prognosis [70].

Recently, it has been reported that the constitutive iNOS expression in melanoma cells might be induced by activation of the MAPK pathway through stimulation of the activity of the Nuclear Factor-kB (NF-kB) [71-72]. NF-kB is a protein complex that acts as a tran‐ scriptional factor and regulates the transcription of several genes involved in many critical pathways [73]. In a quiescent status, proteins of the NF-kB complex are localized into the cytoplasm. NF-κB exists as cytoplasmic hetero- or homodimers associated with members of the inhibitor-of-kB (IkB) proteins (IkB*a*, Ik*Bb* and IkB*e*), which form complexes seques‐ tering NF-kB into the cytoplasm [74]. Upon appropriate stimulation, the phosphorylation of IkB proteins is promoted, triggering their ubiquitination and degradation in the protea‐ some [74]. As a consequence, NF-kB may translocate to the nucleus where it binds to tar‐ get DNA loci and induces transcription of several genes - including *iNOS* - associated with immune and inflammatory response, angiogenesis, cell proliferation, tumor promo‐ tion, and apoptosis [73-74].

Regarding the role of NF-kB in tumorigenesis, there are compelling evidence that activation of NF-kB controls multiple cellular processes in cancer due to its ability to promote cell pro‐ liferation, suppress apoptosis, promote cell migration, and suppress cell differentiation, opening the way for new therapeutic approaches against such a target [75-76]. In melanoma, NF-kB is constitutively activated since expression of the IkB proteins seems to be significant‐ ly reduced in comparison to nevi [77].

#### **2.6.** *cKIT* **and tyrosinase kinase receptors**

velopment and pathogenesis [43, 57]. MITF is activated by the MAPK pathway as well as by the cAMP pathway (Figure 1), and leads to transcription of genes involved in pigmentation (TYR, TYRP1, and DCT; see above) as well as cell cycle progression and survival [43]. The *MITF* gene is amplified in melanoma (about 20% of cases); *MITF* amplification correlated

The connection between MITF and melanoma development is complex because it plays a double role of inducer/repressor of cellular proliferation. High levels of MITF expression lead to G1 cell-cycle arrest and differentiation, through induction of the cell cycle inhibitors p16CDKN2A and p21 [58-59] (Figure 1). Very low or null MITF expression levels predispose to apoptosis whereas inter-mediate MITF expression levels promote cell proliferation [57-59]. Therefore, it is thought that melanoma cells have developed strategies to maintain MITF lev‐ els in the range compatible with tumorigenesis. It has been shown that constitutive ERK ac‐ tivity, stimulated by V600EBRAF in melanoma cells, is associated with MITF ubiquitindependent degradation [60]. Nevertheless, continued expression of MITF is necessary for proliferation and survival of melanoma cells, because it also regulates CDK2 and Bcl-2 genes [61-62]. It has been recently shown that oncogenic BRAF may control intracellular levels of the MITF protein through a fine balance of two opposite mechanisms: a direct reduction of MITF levels, by inducing protein degradation, and an indirect increase of MITF levels, by stimulating transcription factors which increase protein expression levels [63]. Oncogenic *BRAF* mutations are associated with *MITF* amplification in a low fraction (10-15%) of mela‐ nomas [63], suggesting that other mechanisms are likely to be involved in ERK-dependent

Human melanoma cells are known to express the inducible nitric oxide synthase (iNOS) enzyme, which is responsible for synthesis of nitric oxide (NO), a free radical involved in several physiological processes such as neurotransmission, vasodilation, and regulation of immune responses [64]. The iNOS enzyme has been found to be frequently expressed in melanoma [65-66] and the subsequent increased concentrations of NO have been demon‐ strated to contribute to melanomagenesis through a sustained protection of the tumour from apoptosis [67]. However, the role of iNOS in melanoma progression remains contro‐ versial. Higher levels of iNOS have been found in subcutaneous and lymph node metasta‐ ses of non-progressive melanoma as compared to metastases of progressive melanoma [68], however, iNOS was found to be expressed to a lesser extent in metastases as com‐ pared with nevi and primary melanomas [69]. Nevertheless, the expression of iNOS in pa‐ tients with lymph nodes and in-transit metastases (stage III disease) has been proposed as

Recently, it has been reported that the constitutive iNOS expression in melanoma cells might be induced by activation of the MAPK pathway through stimulation of the activity of the Nuclear Factor-kB (NF-kB) [71-72]. NF-kB is a protein complex that acts as a tran‐ scriptional factor and regulates the transcription of several genes involved in many critical pathways [73]. In a quiescent status, proteins of the NF-kB complex are localized into the

with increased resistance to chemotherapy and decreased overall survival [57].

degradation of MITF.

**2.5.** *iNOS* **and** *NF-kB* **pathways**

36 Melanoma - From Early Detection to Treatment

an indicator of poor prognosis [70].

cKIT is a member of the transmenbrane receptor tyrosine kinase family that comprised five immunoglobin-like motifs, a single transmembrane region, an inhibitory cytoplasmic juxta‐ menbrane domain, and a split cytoplasmic kinase domain separated by a kinase insert seg‐ ment [78]. Under physiological conditions, binding of the cKIT ligand stem-cell factor (SCF) to the extracellular domain of the receptor leads its dimerization, activation of the intracellu‐ lar tyrosine kinase domain through autophosporylation of specific tyrosine residue [78]. The intracellular signaling through cKIT plays a critical role in the development of several mam‐ malian cells, including growth, differentiation, migration, and proliferation of melanocytes [79]. It has been defined that cKIT recruits and activates a number of intracellular signaling pathways implicated in tumor progression, such as MAPK, PI3K/AKT, Src, activators of transcription (STAT), and phospholipase-C (PLC) [79-80].

Although the role of cKIT in melanomagenesis is still controversial, several studies have reported its downregulation during melanoma growth and invasion (in vertical growth phase of melanoma and metastatic lesions) [81-83]. Indeed, the majority of highly meta‐ static human melanomas do not express detectable levels of the cKIT receptor [83]. As a confirmation of this, over-expression of cKIT in metastatic melanoma cell lines led to im‐ portant reduction in tumor growth, while cKIT activation through exposure to cKIT li‐ gands induced apoptosis [83].

Specific mutations within the cKIT gene cause constitutive phosphorylation and activation of the kinase domain resulting in uncontrolled cell proliferation. [84]. Although such muta‐ tions seem to be more rare than *BRAF* and *NRAS* mutations, these may reflect the important role of cKIT tyrosine kinase in melanocyte development [84]. Sequencing of cKIT exons 11, 13, 17, and 18 revealed the most prevalent mutation to be K642, L576P, D816H-V, V559A [84]. The cKIT mutations are more common in mucosal and acral melanomas compared with cutaneous melanomas and are in most cases accompanied by an increase in gene copy number (40% mucosal or acral melanomas - frequently, associated with amplification of *cy‐* *clin D1* - as well as 30% of melanomas on skin with chronic sun-induced damage) [84]. High expression levels of cKIT and CDK4 proteins have been identified in another subset of mela‐ nomas lacking *BRAF* mutations [85].

gp100 vaccine alone [median OS 10.0 vs 6.4 mesi; Hazard Ratio (HR) for death, 0.68; p<0,001) [91]. In the second study, Dacarbazine was administered as standard chemotherapeutic drug for melanoma patients, in association with Ipilimumab or placebo; the OS rate was significantly higher in the group of patients treated with Ipilimumab + Dacarbazine (11.2 *vs*. 9.1 months), with even more significant percentages of survival for such an association after one year (47.3% *vs*. 36.3%), two years (28.5% *vs*. 17.9%), or three years (20.8% *vs*. 12.2%) of follow-up [92]. The DFS and OS curves from the two studies have been indicated as largely overlapping, strongly dem‐ onstrating, for the first time in the history of medical treatments for the advanced disease, a clear survival benefit in metastatic (disease stage IV) melanoma. For these reasons, Ipilimumab has

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

39

been recently approved by FDA and EMEA for the treatment of metastatic melanoma.

The different molecular *pathways* involved into the pathogenesis of melanoma are function‐ ally linked each other (Figure 1). There is thus a need to consider such biological cascades as part of a functional web, and the alterations detected in distinct components of the various pathways must be globally considered for the effects determining in such a functional web. This new vision helps in clarifying the reasons by which some alterations may coexist or not in specific melanoma subtypes. As an example, *BRAF* mutations may be observed in con‐ junction with *PI3K* alterations, but none of them may coexist with *NRAS* mutations; since BRAF and PI3K kinases act downstream NRAS protein, occurrence of *NRAS* mutations acti‐ vating both MAPK and PI3K-AKT pathways makes unnecessary the further activation of BRAF and PI3K (upstream effectors of the MAPK and PI3K-AKT pathways, respectively). Analogously, oncogenic *BRAF* mutations are able to more intensively activate ERK protein, main last effector downstream the MAPK pathway, when inactivation of the mechanisms

In an attempt to simplify such complex processes underlying the different phases of devel‐ opment and progression of melanoma, the main pathogenetic molecular alterations may be

**•** oncogenic *BRAF* mutations, genomic rearrangements (mainly represented by allelic dele‐ tions) at the 9p21 chromosome, and increased expression levels of the AKT3 protein are the main alterations involved into the phase of stimulation of the proliferation for normal

**•** impairments of the mechanisms controlling the cell senescence, apoptosis and cell surviv‐ al (which particularly include alterations in the different components of *CDKN2A* path‐ ways: functional deficit of *p16CDKN2A* gene, amplification of *CDK4*-*Cyclin D1*/*CCND1* loci, inattivation of *TP53* gene through a deregulation of the p14CDKN2A-MDM2-p53 functional cascade), oncogenic mutations in *NRAS* gene, activating mutations and, to a lesser extent, gene amplifications of *cKIT* are the main alterations involved into the phase of acquisition of the malignant phenotype which underlay the development of melanoma (*intermediate*

**3. Melanoma subtypes and targeted therapeutic options**

controlling senescence and apoptosis concomitantly occurs.

grouped in the following way:

*neoplastic phase*);

melanocytes (*initial preneoplastic phase*);

### **2.7. CTLA-4 and T-cell activation**

The above-mentioned main intracellular molecular pathways are thus involved in tumor growth and survival, actively participating to the different phases of development and progres‐ sion of melanoma. Additional extracellular factors, mainly represented by different compo‐ nents of the tumor microenvironment, have been implied to play a role in melanoma tissue invasion and metastatic dissemination. As an example, changes in the expression of adhesion molecules such as MCAM/MUC18, E-cadherin, and integrins occur in the transition from the ra‐ dial growth phase (RGP) to the vertical growth phase (VGP) of melanoma; they are induced by both intracellular modifications [i.e., activation of the focal adhesion kinase (FAK) and integrin linked kinase (ILK) patways or high levels of activated ERK (phospoERK1-2)] and biological sig‐ nals directly generated by the extracellular matrix (ECM), which is composed of proteins, glyco‐ proteins, proteoglycans, and glycosaminoglycans in complex arrangements [22-23].

Among others, a block of the anti-tumor immune response induced by changes in pericellular microenvironment has been demonstrated to contribute to melanoma progression [86]. In re‐ cent past years, research has tried to better define the molecular mechanisms underlying the downregulation of the immune system by such pericellular components, in order to develop new therapeutic targets [87]. Actually, two immunomodulant antibodies, such as anti-CTLA4 and anti-PD1, have been demonstrated to be effective in inhibiting some down-regulators of the anti-tumor immune response [30, 88]. Moreover, drugs able to interfere with the differentiation of the myeloid-derived suppressor cells (MDSC) and T regulatory cells (Treg), which are both physiologically involved in controlling an abnormal immune response during the inflammato‐ ry processes and pathologically favoring tumor progression through suppression of T-cell acti‐ vation, represent additional therapeutic strategies to be exploited [89].

For T-cell activation, melanoma antigens that are bound to the major histocompatibility com‐ plex (MHC) on antigen-presenting cells (APCs) require the costimulation of CD28 receptor on Tcells by CD80 or CD86 ligands on APCs [90]. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) can bind with greater affinity to CD80 and CD86, and thus disrupt the necessary costimulatory signal provided by APCs [88, 90]. This led to the hypothesis that blockade of CTLA-4 function may allow for optimal costimulation of CD28 receptors on T-cells by APC CD80/86, and en‐ hanced T-cell activation [88, 90]. Ipilimumab (Yervoy™ Bristol-Myers Squibb, New York, NY) blocks the costimulatory signal required for T-cell activation [30, 88]. In particular, Ipilimumab is a recombinant human IgG1 monoclonal antibody that binds to CTLA-4 and blocks binding to CD80 or CD86 on APCs, thus increasing activation and proliferation of T cells [88]. Two random‐ ized phase III trials have indicated a significant advantage in disease-free survival (DFS) and overall survival (OS) in either monotherapy or combination therapy [91-92]. The first trial com‐ pared monotherapy with Ipilimumab 3 mg/kg, combination of Ipilimumab with gp100 vaccine, and gp100 vaccine alone; the study demonstrated a significant advantage in OS for patients treated with Ipilimumab (regardless the addition off gp100) in comparison to those receiving the gp100 vaccine alone [median OS 10.0 vs 6.4 mesi; Hazard Ratio (HR) for death, 0.68; p<0,001) [91]. In the second study, Dacarbazine was administered as standard chemotherapeutic drug for melanoma patients, in association with Ipilimumab or placebo; the OS rate was significantly higher in the group of patients treated with Ipilimumab + Dacarbazine (11.2 *vs*. 9.1 months), with even more significant percentages of survival for such an association after one year (47.3% *vs*. 36.3%), two years (28.5% *vs*. 17.9%), or three years (20.8% *vs*. 12.2%) of follow-up [92]. The DFS and OS curves from the two studies have been indicated as largely overlapping, strongly dem‐ onstrating, for the first time in the history of medical treatments for the advanced disease, a clear survival benefit in metastatic (disease stage IV) melanoma. For these reasons, Ipilimumab has been recently approved by FDA and EMEA for the treatment of metastatic melanoma.

## **3. Melanoma subtypes and targeted therapeutic options**

*clin D1* - as well as 30% of melanomas on skin with chronic sun-induced damage) [84]. High expression levels of cKIT and CDK4 proteins have been identified in another subset of mela‐

The above-mentioned main intracellular molecular pathways are thus involved in tumor growth and survival, actively participating to the different phases of development and progres‐ sion of melanoma. Additional extracellular factors, mainly represented by different compo‐ nents of the tumor microenvironment, have been implied to play a role in melanoma tissue invasion and metastatic dissemination. As an example, changes in the expression of adhesion molecules such as MCAM/MUC18, E-cadherin, and integrins occur in the transition from the ra‐ dial growth phase (RGP) to the vertical growth phase (VGP) of melanoma; they are induced by both intracellular modifications [i.e., activation of the focal adhesion kinase (FAK) and integrin linked kinase (ILK) patways or high levels of activated ERK (phospoERK1-2)] and biological sig‐ nals directly generated by the extracellular matrix (ECM), which is composed of proteins, glyco‐

proteins, proteoglycans, and glycosaminoglycans in complex arrangements [22-23].

vation, represent additional therapeutic strategies to be exploited [89].

Among others, a block of the anti-tumor immune response induced by changes in pericellular microenvironment has been demonstrated to contribute to melanoma progression [86]. In re‐ cent past years, research has tried to better define the molecular mechanisms underlying the downregulation of the immune system by such pericellular components, in order to develop new therapeutic targets [87]. Actually, two immunomodulant antibodies, such as anti-CTLA4 and anti-PD1, have been demonstrated to be effective in inhibiting some down-regulators of the anti-tumor immune response [30, 88]. Moreover, drugs able to interfere with the differentiation of the myeloid-derived suppressor cells (MDSC) and T regulatory cells (Treg), which are both physiologically involved in controlling an abnormal immune response during the inflammato‐ ry processes and pathologically favoring tumor progression through suppression of T-cell acti‐

For T-cell activation, melanoma antigens that are bound to the major histocompatibility com‐ plex (MHC) on antigen-presenting cells (APCs) require the costimulation of CD28 receptor on Tcells by CD80 or CD86 ligands on APCs [90]. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) can bind with greater affinity to CD80 and CD86, and thus disrupt the necessary costimulatory signal provided by APCs [88, 90]. This led to the hypothesis that blockade of CTLA-4 function may allow for optimal costimulation of CD28 receptors on T-cells by APC CD80/86, and en‐ hanced T-cell activation [88, 90]. Ipilimumab (Yervoy™ Bristol-Myers Squibb, New York, NY) blocks the costimulatory signal required for T-cell activation [30, 88]. In particular, Ipilimumab is a recombinant human IgG1 monoclonal antibody that binds to CTLA-4 and blocks binding to CD80 or CD86 on APCs, thus increasing activation and proliferation of T cells [88]. Two random‐ ized phase III trials have indicated a significant advantage in disease-free survival (DFS) and overall survival (OS) in either monotherapy or combination therapy [91-92]. The first trial com‐ pared monotherapy with Ipilimumab 3 mg/kg, combination of Ipilimumab with gp100 vaccine, and gp100 vaccine alone; the study demonstrated a significant advantage in OS for patients treated with Ipilimumab (regardless the addition off gp100) in comparison to those receiving the

nomas lacking *BRAF* mutations [85].

**2.7. CTLA-4 and T-cell activation**

38 Melanoma - From Early Detection to Treatment

The different molecular *pathways* involved into the pathogenesis of melanoma are function‐ ally linked each other (Figure 1). There is thus a need to consider such biological cascades as part of a functional web, and the alterations detected in distinct components of the various pathways must be globally considered for the effects determining in such a functional web. This new vision helps in clarifying the reasons by which some alterations may coexist or not in specific melanoma subtypes. As an example, *BRAF* mutations may be observed in con‐ junction with *PI3K* alterations, but none of them may coexist with *NRAS* mutations; since BRAF and PI3K kinases act downstream NRAS protein, occurrence of *NRAS* mutations acti‐ vating both MAPK and PI3K-AKT pathways makes unnecessary the further activation of BRAF and PI3K (upstream effectors of the MAPK and PI3K-AKT pathways, respectively). Analogously, oncogenic *BRAF* mutations are able to more intensively activate ERK protein, main last effector downstream the MAPK pathway, when inactivation of the mechanisms controlling senescence and apoptosis concomitantly occurs.

In an attempt to simplify such complex processes underlying the different phases of devel‐ opment and progression of melanoma, the main pathogenetic molecular alterations may be grouped in the following way:

**•** complete silencing of *p16CDKN2A* gene, functional loss of PTEN, activation of the PI3K-AKT pathway, and amplification of the *MITF* gene are the main alterations involved into the phase of acquisition of a more aggressive and invasive phenotype which underlay the progression and dissemination of melanoma (*final metasticase phase*).

Nevertheless, all these evidence represent a strong indication that the different molecular pathways associated with the melanomagenesis does correspond to different subsets of mel‐ anoma patients, with distinguished biological and clinical behavior of the disease. Identifica‐ tion of such different patients' subsets should be introduced in clinical trials, in order to better assess the classification of all predictive and prognostic factors associated with the disease as well as more accurately address patients to the most effective therapeutic inter‐

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

41

On the basis of the presence of the specific molecular features, a discrimination of the main subtypes of melanoma, along with the more appropriate therapeutic option for each sub‐

Prevalence of *BRAF* mutations, with tendency to increased expression level of activated ERK (phospoERK1-2) in melanoma tissues. This subtype benefits by the treatment with inhibitors

After failure of BAY 43-9006 (which is not specific for mutated BRAF, but suppresses activi‐ ty of several different kinases [95]), a second generation BRAF inhibitor (Vemurafenib, also known as PLX4032 or RO5185426) was highly specific for V600EBRAF mutation and appeared very promising from the clinical point of view [96]. Very recently, results from a phase III study comparing the vemurafenib to dacarbazine have been indeed reported, indicating a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine [97]. Preliminary data using an additional V600EBRAF inhibitor compound, Dabrafenib (previously known as GSK2118436), seemed to point out that this molecule is also active on V600KBRAF and V600DBRAF mutations [98]; actual‐ ly, treatment with such a compound is under evaluation in a phase III study among BRAF

However, preliminary data seem to indicate that a large variety of induced alterations may drive resistance to BRAF inhibitors: upregulation of the receptor tyrosine kinase (RTK) effec‐ tors [99], mutation in *NRAS* gene and platelet-derived growth factor receptor β (PDGFRβ) [99], amplification of the *CCND1/Cyclin D1* gene or lack of phosphatase-and-tensin homo‐ logue (PTEN) function [100], mutations in downstream *MEK* gene [101], activation of MAPK pathway agonists such as COT kinase [102], or enhancement of the IGF-1R/PI3K signaling

The MEK inhibitors (AS703026, E6201, GSK1120212, GDC0973, MEK162) as single agents have activity against melanoma, in patients either carrying BRAF mutations and unexposed to prior BRAF inhibitor therapy or presenting NRAS mutations [30]. A new combination of MEK and BRAF inhibitors as first line therapy for BRAF mutated melanoma patients naïve

The *BRAF* mutations may coexist with additional molecular alterations, with subsequent

constitution of further biological and molecular subgroups of melanoma patients:

vention according to their biological and molecular status.

type, could be schematically reported.

mutation positive stage III-IV melanoma patients.

[103]. These findings highlight the need for combination therapy.

to prior anti-BRAF treatment is showing great promise [30].

**1.** Subtype MAPK

of BRAF.

All these findings clearly indicate the existence of a complex molecular machinery that pro‐ vides checks and balances in normal melanocytes, allowing a physiologically controlled cell proliferation. Progression from normal melanocytes to malignant metastatic cell in melano‐ ma patients is the result of a combination of down- or up-regulations of the various effectors acting into the different molecular pathways. According to this, it has been proposed a line‐ ar model of pathogenesis of melanoma based on the sequential accumulation of most of the previously-described molecular alterations (Figure 2A) [7, 13, 93]. In a limited fraction of cases, it has been recently hypothesized a second non-linear model of melanomagenesis based on accumulation of the same genetic alterations in tissue stem cells, with generation of malignant cells directly forming RGP or VGP or metastatic melanoma lesions (Figure 2B) [94]. This latter hypothesis has been derived by the evidence of some inconsistencies of the linear model in subgroups of melanomas (i.e., incidence of *BRAF* mutations higher in VGP lesions than that found in RGP lesions [94]).

**Figure 2.** Models of development and progression for melanoma. A, sequential model. B, non-linear model.

Nevertheless, all these evidence represent a strong indication that the different molecular pathways associated with the melanomagenesis does correspond to different subsets of mel‐ anoma patients, with distinguished biological and clinical behavior of the disease. Identifica‐ tion of such different patients' subsets should be introduced in clinical trials, in order to better assess the classification of all predictive and prognostic factors associated with the disease as well as more accurately address patients to the most effective therapeutic inter‐ vention according to their biological and molecular status.

On the basis of the presence of the specific molecular features, a discrimination of the main subtypes of melanoma, along with the more appropriate therapeutic option for each sub‐ type, could be schematically reported.

### **1.** Subtype MAPK

**•** complete silencing of *p16CDKN2A* gene, functional loss of PTEN, activation of the PI3K-AKT pathway, and amplification of the *MITF* gene are the main alterations involved into the phase of acquisition of a more aggressive and invasive phenotype which underlay the

All these findings clearly indicate the existence of a complex molecular machinery that pro‐ vides checks and balances in normal melanocytes, allowing a physiologically controlled cell proliferation. Progression from normal melanocytes to malignant metastatic cell in melano‐ ma patients is the result of a combination of down- or up-regulations of the various effectors acting into the different molecular pathways. According to this, it has been proposed a line‐ ar model of pathogenesis of melanoma based on the sequential accumulation of most of the previously-described molecular alterations (Figure 2A) [7, 13, 93]. In a limited fraction of cases, it has been recently hypothesized a second non-linear model of melanomagenesis based on accumulation of the same genetic alterations in tissue stem cells, with generation of malignant cells directly forming RGP or VGP or metastatic melanoma lesions (Figure 2B) [94]. This latter hypothesis has been derived by the evidence of some inconsistencies of the linear model in subgroups of melanomas (i.e., incidence of *BRAF* mutations higher in VGP

**Figure 2.** Models of development and progression for melanoma. A, sequential model. B, non-linear model.

progression and dissemination of melanoma (*final metasticase phase*).

lesions than that found in RGP lesions [94]).

40 Melanoma - From Early Detection to Treatment

Prevalence of *BRAF* mutations, with tendency to increased expression level of activated ERK (phospoERK1-2) in melanoma tissues. This subtype benefits by the treatment with inhibitors of BRAF.

After failure of BAY 43-9006 (which is not specific for mutated BRAF, but suppresses activi‐ ty of several different kinases [95]), a second generation BRAF inhibitor (Vemurafenib, also known as PLX4032 or RO5185426) was highly specific for V600EBRAF mutation and appeared very promising from the clinical point of view [96]. Very recently, results from a phase III study comparing the vemurafenib to dacarbazine have been indeed reported, indicating a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine [97]. Preliminary data using an additional V600EBRAF inhibitor compound, Dabrafenib (previously known as GSK2118436), seemed to point out that this molecule is also active on V600KBRAF and V600DBRAF mutations [98]; actual‐ ly, treatment with such a compound is under evaluation in a phase III study among BRAF mutation positive stage III-IV melanoma patients.

However, preliminary data seem to indicate that a large variety of induced alterations may drive resistance to BRAF inhibitors: upregulation of the receptor tyrosine kinase (RTK) effec‐ tors [99], mutation in *NRAS* gene and platelet-derived growth factor receptor β (PDGFRβ) [99], amplification of the *CCND1/Cyclin D1* gene or lack of phosphatase-and-tensin homo‐ logue (PTEN) function [100], mutations in downstream *MEK* gene [101], activation of MAPK pathway agonists such as COT kinase [102], or enhancement of the IGF-1R/PI3K signaling [103]. These findings highlight the need for combination therapy.

The MEK inhibitors (AS703026, E6201, GSK1120212, GDC0973, MEK162) as single agents have activity against melanoma, in patients either carrying BRAF mutations and unexposed to prior BRAF inhibitor therapy or presenting NRAS mutations [30]. A new combination of MEK and BRAF inhibitors as first line therapy for BRAF mutated melanoma patients naïve to prior anti-BRAF treatment is showing great promise [30].

The *BRAF* mutations may coexist with additional molecular alterations, with subsequent constitution of further biological and molecular subgroups of melanoma patients:

**a.** Impairment of the p16CDKN2A-CDK4/CCND1-RB or p14CDKN2A-MDM2-TP53 pathways, with reduced expression of the p16CDKN2A protein and tendency to amplification of the *CDK4*/*CCND1* gene loci or inactivation of the TP53 gene (with consequent functional loss of the p53 protein), respectively. This subtype benefits by the treatment with inhibi‐ tors of the cyclin-dependent kinases.

To date, two approaches have been considered in developing drugs against RAS. The first is based on the block of farnesylation. A small clinical trial using an inhibitor of the farnesyl transferase enzyme failed to be efficacious in a melanoma cohort; however, patients includ‐ ed into such a study were not selected on the basis of their *NRAS* mutation status [112-113]. In the light of recent successes of the target therapies based on anti-BRAF or anti-cKIT inhib‐ itors, a more stringently selected cohort carrying alterations in *NRAS* gene would have in‐ creased responsiveness. On the other hand, a direct targeting of RAS has been demonstrated to be very difficult [114]; this is the reason why therapeutic strategies have focused on inhib‐ iting downstream effectors into the pathways activated by RAS (i.e., MEK inhibitors for the MAPK pathway - see above - and mTORC inhibitors for the PI3K-AKT pathway - see be‐

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

43

Prevalence of *cKIT* mutations ± gene amplification and/or increased protein expression lev‐ els. This subtype benefits by the treatment with inhibitors of cKIT (in particular, patients carrying gene mutations, with some sequence variants - such as K642E e L576P - which are

Activating cKIT mutations have been implicated in a variety of cancers, mainly represented by gastrointestinal stromal tumors (GIST) and chronic myelogenous leukemia (CML). This is the reason why several drugs targeting cKIT have been developed and tested in clinical trials, including Imatinib (approved for Philadelphia chromosome–positive CML and cKITpositive GIST) and Sunitib (approved for advanced kidney cancer and Imatinib-resistant GIST) as well as Nilotinib and Dasatinib (approved for CML and Philadelphia chromosome-

The inhibitors of cKIT that may have a therapeutic benefit in melanoma, by inducing cell cy‐ cle arrest and apoptosis as well as significantly inhibiting cell migration and invasion of tu‐

Imatinib mesylate, formerly known as STI571, is designated chemically as 4-benzamide methanesulfonate. The efficacy of imatinib varies with the site of cKIT mutation; moreover, this drug can inhibit both the wild-type receptor activated by ligand and mutated receptor in the absence of ligand. However, imatinib is less effective at inhibiting the receptor with

Nilotinib (AMN107), which has been rationally designed based on the imatinib mesylate scaffold to have a more selective action. On this regard, Nilotinib inhibits both wild-type and cKIT mutants in exon 11 (V560del and V560G), exon 13 (K642E), double mutants in‐ volving exons 11, 13, and 17 as well as imatinib-resistant cKIT mutant (V560del/V654A)

Dasatinib, which is a piperazinyl ethanol exhibiting increased potency but reduced selectivi‐ ty compared with imatinib mesylate, has been demonstrated to inhibit both wild type and mutant cKIT in a dose-dependent manner, causing inhibition of cell migration and invasion through reduction of the phosphorylation of either Src kinase and FAK pathway [116-117].

low), which represent the second treatment approach against RAS.

**3.** Subtype cKIT

highly responsive).

mor cells, are:

cells [115];

positive acute lymphoblastic leukemia).

mutations in the enzymatic site (exon 17 mutations) [79];

Melanoma patients carrying genetic alterations affecting p16CDKN2A could potentially be treated with inhibitors of CDK4/CDK6. There are currently no validated therapeutic options for melanoma with mutated p14CDKN2A. Conversely, several CDK4 inhibitors (Alvocidib, AT-7519, P1446A-05, PD-0332991, Flavopiridol/alvocidib/HMR 1275, P276-00, R547, SNS-032/ BMS-387032, UCN-01, ZK 304709/MTGI) are currently under investigation for a variety of cancer types, including metastatic melanoma, and results are awaited. For p53, there are currently no drugs, approved or in trials, against such a target. Conversely, an an‐ ti-sense agent (Oblimersen) targeted at nuclear Bcl-2 has been evaluated in trials, failing to demonstrate a significant clinical benefit among patients with melanoma [104].

**b.** Amplification of *MITF* ± associated with reduction of the protein expression levels.

No drug targeting MITF has been developed; however, expression of MITF has been dem‐ onstrated to be reduced by compounds inhibiting the multiple histone deacetylase (HDAC) complex [105]. Ongoing trials based on HDAC-inhibitors [LBH589 (Panobinostat) or Valpro‐ ic acid (Vorinostat)] will elucidate whether a clinical benefit could be obtained by down-reg‐ ulating intracellular level of MITF protein.

**c.** Activation of NF-kB.

Proteasome inhibitors, such as Bortezomib (Velcade, previously known as PS-341), represent a new class of anticancer therapeutic agents which inhibit degradation of important cell cy‐ cle and/or regulatory proteins, including IkB [106-107]. Bortezomid has been demonstrated to contribute in maintaining integrity of the complexes sequestering NF-kB into the cyto‐ plasm, thus reducing the NF-kB activity [106-107]. Phase 2 studies combinating Bortezomib with other chemotherapeutic agents, including paclitaxel, carboplatin, or temozolomide equally have been established [108-109]. A compound that more directly targets the NF-kB pathway is BMS-345541 (4(2'-aminoethyl) amino-1,8-dimethylimidazo(1,2-a)quinoxaline), identified as a selective inhibitor of the catalytic subunits of IKK that binds at an allosteric site of the enzyme [110].

Since mutational activation of BRAF in human melanomas has been demonstrated to con‐ tribute to constitutive induction of NF-kB activity through an increase of the IKK activity [111], inhibition of BRAF signaling using the above mentioned inhibitors may decrease the NF-kB transcriptional activity and sensitize melanoma cells to apoptosis.

#### **2.** Subtype NRAS

Prevalence of *NRAS* mutation, with markedly increased expression level of activated ERK (phospoERK1-2) and eventual activation of AKT. This subtype benefits by the treatment with inhibitors of MEK or mTORC.

To date, two approaches have been considered in developing drugs against RAS. The first is based on the block of farnesylation. A small clinical trial using an inhibitor of the farnesyl transferase enzyme failed to be efficacious in a melanoma cohort; however, patients includ‐ ed into such a study were not selected on the basis of their *NRAS* mutation status [112-113]. In the light of recent successes of the target therapies based on anti-BRAF or anti-cKIT inhib‐ itors, a more stringently selected cohort carrying alterations in *NRAS* gene would have in‐ creased responsiveness. On the other hand, a direct targeting of RAS has been demonstrated to be very difficult [114]; this is the reason why therapeutic strategies have focused on inhib‐ iting downstream effectors into the pathways activated by RAS (i.e., MEK inhibitors for the MAPK pathway - see above - and mTORC inhibitors for the PI3K-AKT pathway - see be‐ low), which represent the second treatment approach against RAS.

## **3.** Subtype cKIT

**a.** Impairment of the p16CDKN2A-CDK4/CCND1-RB or p14CDKN2A-MDM2-TP53 pathways, with reduced expression of the p16CDKN2A protein and tendency to amplification of the *CDK4*/*CCND1* gene loci or inactivation of the TP53 gene (with consequent functional loss of the p53 protein), respectively. This subtype benefits by the treatment with inhibi‐

Melanoma patients carrying genetic alterations affecting p16CDKN2A could potentially be treated with inhibitors of CDK4/CDK6. There are currently no validated therapeutic options for melanoma with mutated p14CDKN2A. Conversely, several CDK4 inhibitors (Alvocidib, AT-7519, P1446A-05, PD-0332991, Flavopiridol/alvocidib/HMR 1275, P276-00, R547, SNS-032/ BMS-387032, UCN-01, ZK 304709/MTGI) are currently under investigation for a variety of cancer types, including metastatic melanoma, and results are awaited. For p53, there are currently no drugs, approved or in trials, against such a target. Conversely, an an‐ ti-sense agent (Oblimersen) targeted at nuclear Bcl-2 has been evaluated in trials, failing to

demonstrate a significant clinical benefit among patients with melanoma [104].

**b.** Amplification of *MITF* ± associated with reduction of the protein expression levels.

No drug targeting MITF has been developed; however, expression of MITF has been dem‐ onstrated to be reduced by compounds inhibiting the multiple histone deacetylase (HDAC) complex [105]. Ongoing trials based on HDAC-inhibitors [LBH589 (Panobinostat) or Valpro‐ ic acid (Vorinostat)] will elucidate whether a clinical benefit could be obtained by down-reg‐

Proteasome inhibitors, such as Bortezomib (Velcade, previously known as PS-341), represent a new class of anticancer therapeutic agents which inhibit degradation of important cell cy‐ cle and/or regulatory proteins, including IkB [106-107]. Bortezomid has been demonstrated to contribute in maintaining integrity of the complexes sequestering NF-kB into the cyto‐ plasm, thus reducing the NF-kB activity [106-107]. Phase 2 studies combinating Bortezomib with other chemotherapeutic agents, including paclitaxel, carboplatin, or temozolomide equally have been established [108-109]. A compound that more directly targets the NF-kB pathway is BMS-345541 (4(2'-aminoethyl) amino-1,8-dimethylimidazo(1,2-a)quinoxaline), identified as a selective inhibitor of the catalytic subunits of IKK that binds at an allosteric

Since mutational activation of BRAF in human melanomas has been demonstrated to con‐ tribute to constitutive induction of NF-kB activity through an increase of the IKK activity [111], inhibition of BRAF signaling using the above mentioned inhibitors may decrease the

Prevalence of *NRAS* mutation, with markedly increased expression level of activated ERK (phospoERK1-2) and eventual activation of AKT. This subtype benefits by the treatment with

NF-kB transcriptional activity and sensitize melanoma cells to apoptosis.

tors of the cyclin-dependent kinases.

42 Melanoma - From Early Detection to Treatment

ulating intracellular level of MITF protein.

**c.** Activation of NF-kB.

site of the enzyme [110].

**2.** Subtype NRAS

inhibitors of MEK or mTORC.

Prevalence of *cKIT* mutations ± gene amplification and/or increased protein expression lev‐ els. This subtype benefits by the treatment with inhibitors of cKIT (in particular, patients carrying gene mutations, with some sequence variants - such as K642E e L576P - which are highly responsive).

Activating cKIT mutations have been implicated in a variety of cancers, mainly represented by gastrointestinal stromal tumors (GIST) and chronic myelogenous leukemia (CML). This is the reason why several drugs targeting cKIT have been developed and tested in clinical trials, including Imatinib (approved for Philadelphia chromosome–positive CML and cKITpositive GIST) and Sunitib (approved for advanced kidney cancer and Imatinib-resistant GIST) as well as Nilotinib and Dasatinib (approved for CML and Philadelphia chromosomepositive acute lymphoblastic leukemia).

The inhibitors of cKIT that may have a therapeutic benefit in melanoma, by inducing cell cy‐ cle arrest and apoptosis as well as significantly inhibiting cell migration and invasion of tu‐ mor cells, are:

Imatinib mesylate, formerly known as STI571, is designated chemically as 4-benzamide methanesulfonate. The efficacy of imatinib varies with the site of cKIT mutation; moreover, this drug can inhibit both the wild-type receptor activated by ligand and mutated receptor in the absence of ligand. However, imatinib is less effective at inhibiting the receptor with mutations in the enzymatic site (exon 17 mutations) [79];

Nilotinib (AMN107), which has been rationally designed based on the imatinib mesylate scaffold to have a more selective action. On this regard, Nilotinib inhibits both wild-type and cKIT mutants in exon 11 (V560del and V560G), exon 13 (K642E), double mutants in‐ volving exons 11, 13, and 17 as well as imatinib-resistant cKIT mutant (V560del/V654A) cells [115];

Dasatinib, which is a piperazinyl ethanol exhibiting increased potency but reduced selectivi‐ ty compared with imatinib mesylate, has been demonstrated to inhibit both wild type and mutant cKIT in a dose-dependent manner, causing inhibition of cell migration and invasion through reduction of the phosphorylation of either Src kinase and FAK pathway [116-117].

## **4.** Subtype mTORC

Prevalence of PTEN loss (± *PI3K* mutations, which are mostly infrequent) and phosphoryla‐ tion of AKT, with absence of concurrent mutations in *BRAF* gene. This subtype mainly bene‐ fits by the treatment with inhibitors of mTOR.

**•** Acral melanoma

damage (CSD)

(non-CSD)

**•** Mucosal melanoma

**•** Uveal melanoma

cases).

and/or 5p15 genomic loci.

± amplification of *cKIT* (in about 5% of cases).

Mutation ± amplification of *cKIT*; amplification of *CDK4* or *CCND1* (associated with in‐ creased expression levels of the related proteins); amplification of the 11q13, 22q11-13,

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

45

**•** Melanoma of the head and neck district and melanoma on skin with chronic sun-induced

Amplification of *CDK4* and/or *CCND1*; increased expression levels of p53 protein; mutation

**•** Melanoma of the trunk and melanoma on skin without chronic sun-induced damage

Mutation of *BRAF* or, alternatively, *NRAS* (with eventual coexistence of molecolar altera‐ tions which may ba associated with BRAF mutations; see above); tendency to reduced ex‐

Mutation ± amplification of *cKIT*; amplification of *CDK4* or *CCND1* (associated with in‐ creased expression levels of the related proteins); mutation of *BRAF* (in less than 10% of

Knowledge of the principal molecular alterations to be tested in patients with such distinct subtypes of melanoma will be of great clinical importance, because it is likely to result in separate targeted therapeutic approaches and prevention strategies. To date, it has been al‐ ready developed a panel of molecular tests to be performed in patients with melanoma from different anatomical locations (Figure 3). This initial "*flow-chart*" will surely become more detailed and enriched on the basis of the progressive identification and validation of addi‐

Finally, recent meta-analyses tried to define the prognostic role of majority of molecular al‐

loss of p53; over-expression of iNOS, AP-2, MMP-2 and metallothioneine; increased prolifer‐

reduced expression or loss of p16CDKN2A; over-expression of Bcl-2 and ATF-2 (± associated

with simultaneous increases expression of beta-catenin, fibronectin and p21 proteins).

pression of the p53 protein; occurrence of specific polymorphisms in *MC1R* gene.

Mutation ± amplification of *cKIT*; mutation of *GNAQ* and/or *GNA11*.

tional genetics and molecular alterations correlated with the disease.

terations previously described [124-125]:

ation index (high expression levels of Ki-67);

**•** negative prognostic factors

**•** positive prognostic factors

In melanoma cells, three potential targets may be considered for therapeutic intervention against this pathway: AKT, PI3K and mTOR. Restoration of functional PTEN or interfering with AKT and PI3K activity would increase chemosensitivity to apoptotic agents and im‐ prove the efficacy of anti-tumor treatment. Several inhibitors of PI3K (BKM120, BEZ235, BGT226, GDC0941, PX-866, SF1126, and XL147) and AKT (GSK690693, MK2206, and VQD-002) have been developed; results of ongoing trials are thus awaited. To date, clinical trials using agents against the PI3K/AKT pathway have failed to demonstrate significant ef‐ ficacy [118]. However, one therapeutic approach which seems to inhibit this pathway is based on the use of mTOR inhibitors [119]: rapamycin, Temsirolimus (CCI-779), Everolimus (RAD001), Sirolimus and AZD8055. While controversial data have been reported for rapa‐ mycin (suppressing disease progression in some patients with glioblastoma but ineffective in controlling the disease in others) [120], a limited advantage in response rates has been so far described for Temsirolimus [121]. It is to be underlined that none of the trials with mTOR inhibitors included patients specifically selected for alterations in the AKT/PI3K pathway. Several clinical trials are investigating specific combinations of mTOR inhibitors and chemo‐ therapy drugs in the treatment of melanoma.

**5.** Subtype GNAQ/GNA11

Prevalence of *GNAQ/GNA11* mutations, with increased expression level of phosphoERK. This subtype benefits by the treatment with inhibitors of MEK.

The *GNAQ* and *GNA11* genes encodes specific GTP binding proteins that mediate signal transduction from the inner cell surface to the MAPK pathway through activation of the protein kinase C (PKC) enzyme [122]. Somatic mutations in *GNAQ* gene have been observed in about 90% of blue naevi, 50% of malignant blue naevi and 50% of primary uveal melano‐ ma; conversely, the *GNA11* mutations have been found in less than 10% of blue nevi, about one third of primary uveal melanomas, and about 60% of metastatic uveal melanoma [122]. Since mutations in these two genes have non been detected among all the remaining types of melanoma (cutaneous, acral, mucosal), a clinical trial aimed at testing efficacy of a MEK inhibitor, Dabrafenib/GSK1120212, has been focused on patients with metastatic uveal mela‐ noma carrying *GNAQ* and/or *GNA11* mutations [123].

## **4. Diagnostic panel of molecular alterations**

The most prevalent molecular alterations within the heterogeneous patterns of biological features which characterize the distinct subtypes of melanoma are here summarized, accord‐ ing to the anatomical site of melanoma onset, the degree of exposure to the sun, and the his‐ tologic characteristics of the tumor lesions.

## **•** Acral melanoma

**4.** Subtype mTORC

44 Melanoma - From Early Detection to Treatment

fits by the treatment with inhibitors of mTOR.

therapy drugs in the treatment of melanoma.

This subtype benefits by the treatment with inhibitors of MEK.

noma carrying *GNAQ* and/or *GNA11* mutations [123].

**4. Diagnostic panel of molecular alterations**

tologic characteristics of the tumor lesions.

**5.** Subtype GNAQ/GNA11

Prevalence of PTEN loss (± *PI3K* mutations, which are mostly infrequent) and phosphoryla‐ tion of AKT, with absence of concurrent mutations in *BRAF* gene. This subtype mainly bene‐

In melanoma cells, three potential targets may be considered for therapeutic intervention against this pathway: AKT, PI3K and mTOR. Restoration of functional PTEN or interfering with AKT and PI3K activity would increase chemosensitivity to apoptotic agents and im‐ prove the efficacy of anti-tumor treatment. Several inhibitors of PI3K (BKM120, BEZ235, BGT226, GDC0941, PX-866, SF1126, and XL147) and AKT (GSK690693, MK2206, and VQD-002) have been developed; results of ongoing trials are thus awaited. To date, clinical trials using agents against the PI3K/AKT pathway have failed to demonstrate significant ef‐ ficacy [118]. However, one therapeutic approach which seems to inhibit this pathway is based on the use of mTOR inhibitors [119]: rapamycin, Temsirolimus (CCI-779), Everolimus (RAD001), Sirolimus and AZD8055. While controversial data have been reported for rapa‐ mycin (suppressing disease progression in some patients with glioblastoma but ineffective in controlling the disease in others) [120], a limited advantage in response rates has been so far described for Temsirolimus [121]. It is to be underlined that none of the trials with mTOR inhibitors included patients specifically selected for alterations in the AKT/PI3K pathway. Several clinical trials are investigating specific combinations of mTOR inhibitors and chemo‐

Prevalence of *GNAQ/GNA11* mutations, with increased expression level of phosphoERK.

The *GNAQ* and *GNA11* genes encodes specific GTP binding proteins that mediate signal transduction from the inner cell surface to the MAPK pathway through activation of the protein kinase C (PKC) enzyme [122]. Somatic mutations in *GNAQ* gene have been observed in about 90% of blue naevi, 50% of malignant blue naevi and 50% of primary uveal melano‐ ma; conversely, the *GNA11* mutations have been found in less than 10% of blue nevi, about one third of primary uveal melanomas, and about 60% of metastatic uveal melanoma [122]. Since mutations in these two genes have non been detected among all the remaining types of melanoma (cutaneous, acral, mucosal), a clinical trial aimed at testing efficacy of a MEK inhibitor, Dabrafenib/GSK1120212, has been focused on patients with metastatic uveal mela‐

The most prevalent molecular alterations within the heterogeneous patterns of biological features which characterize the distinct subtypes of melanoma are here summarized, accord‐ ing to the anatomical site of melanoma onset, the degree of exposure to the sun, and the his‐ Mutation ± amplification of *cKIT*; amplification of *CDK4* or *CCND1* (associated with in‐ creased expression levels of the related proteins); amplification of the 11q13, 22q11-13, and/or 5p15 genomic loci.

**•** Melanoma of the head and neck district and melanoma on skin with chronic sun-induced damage (CSD)

Amplification of *CDK4* and/or *CCND1*; increased expression levels of p53 protein; mutation ± amplification of *cKIT* (in about 5% of cases).

**•** Melanoma of the trunk and melanoma on skin without chronic sun-induced damage (non-CSD)

Mutation of *BRAF* or, alternatively, *NRAS* (with eventual coexistence of molecolar altera‐ tions which may ba associated with BRAF mutations; see above); tendency to reduced ex‐ pression of the p53 protein; occurrence of specific polymorphisms in *MC1R* gene.

**•** Mucosal melanoma

Mutation ± amplification of *cKIT*; amplification of *CDK4* or *CCND1* (associated with in‐ creased expression levels of the related proteins); mutation of *BRAF* (in less than 10% of cases).

**•** Uveal melanoma

Mutation ± amplification of *cKIT*; mutation of *GNAQ* and/or *GNA11*.

Knowledge of the principal molecular alterations to be tested in patients with such distinct subtypes of melanoma will be of great clinical importance, because it is likely to result in separate targeted therapeutic approaches and prevention strategies. To date, it has been al‐ ready developed a panel of molecular tests to be performed in patients with melanoma from different anatomical locations (Figure 3). This initial "*flow-chart*" will surely become more detailed and enriched on the basis of the progressive identification and validation of addi‐ tional genetics and molecular alterations correlated with the disease.

Finally, recent meta-analyses tried to define the prognostic role of majority of molecular al‐ terations previously described [124-125]:

**•** negative prognostic factors

loss of p53; over-expression of iNOS, AP-2, MMP-2 and metallothioneine; increased prolifer‐ ation index (high expression levels of Ki-67);

**•** positive prognostic factors

reduced expression or loss of p16CDKN2A; over-expression of Bcl-2 and ATF-2 (± associated with simultaneous increases expression of beta-catenin, fibronectin and p21 proteins).

resistance to BRAF inhibitors [131-134]. BRAF and MEK targeted synergic therapy is cur‐ rently tested in a phase I clinical trial (NCT01072175) which combines the selective RAF in‐ hibitor GSK2118436 with the MEK inhibitor GSK1120212 in patients with BRAF mutant

After decades without perspective, the history of medical treatment for the advanced mela‐ noma is rapidly changing. Combined therapeutic approaches do represent the next chal‐

Authors are always grateful to patients for their cooperation into the various studies. Work was funded by Regione Autonoma della Sardegna and Ricerca Finalizzata Ministero della

, Maria Cristina Sini1

1 Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research

2 Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione

3 University Hospital Health Unit - Azienda Ospedaliero Universitaria (AOU), Via Matteot‐

[1] Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds). Can‐ cer Incidence in Five Continents, Vol. IX, International Agency for Research on Can‐

[2] Linos E, Swetter S, Cockburn MG, et al. Increasing burden of melanoma in the Unit‐

[3] Rigel DS. Epidemiology of melanoma. Semin. Cutan. Med. Surg. 2010; 29: 204-209

, Paolo Antonio Ascierto2

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

47

,

tumors [135].

Salute.

**Acknowledgments**

**Author details**

Amelia Lissia3

ti, Sassari, Italy

**References**

Giuseppe Palmieri1\*, Maria Colombino1

and Antonio Cossu3

"G. Pascale", Via Mariano Semmola, Napoli, Italy

\*Address all correspondence to<EMAIL_ADDRESS>
Council (CNR), Traversa La Crucca, 3 - Baldinca Li Punti, Sassari, Italy

cer (IARC) Scientific Publications, No. 160, Lyon, IARC, 2007.

ed States. J Invest Derm. 2009;129: 1666-74

lenge for treatment of patients with such a disease.

**Figure 3. Principal genetic and molecular tests on tumor tissues for the different types of melanoma.** Amp, gene amplification detected by *fluorescence in situ hybridization* (FISH) analysis. Exp, protein expression level detected by immunohistochemistry. Mut, gene sequence variation detected by mutation analysis. In red, tests for less prevalent alterations.

## **5. Conclusion**

Taken together all the described molecular mechanisms involved in melanoma genesis and progression, data seem to emphasize the fact that in melanoma, but probably in all types of cancer, it is unlikely that targeting a single component in the signalling pathway will yield significant anti-tumour responses. For this purpose, molecular analyses could help clinicians to define the prognosis (prognostic value) as well as to make a prediction, identifying the subsets of patients who would be expected to be more or less likely to respond to specific therapeutic interventions (predictive value).

In other words, it is becoming evident that combination therapies targeting simultaneously several signaling pathways might be a winning therapeutic strategy to treat melanoma pa‐ tients. Preclinical studies using combination of anti BRAF and AKT3 siRNA demonstrated a significantly higher reduction of tumor growth compared to single agent administration [126-127]. There is also evidence of synergism among MEK and PI3K inhibitors as well as promising results have been obtained by combinations of the mTOR inhibitors and sorafe‐ nib or MEK inhibitors [121, 128-129]. In contrast to single agent activity, these combinations of target drugs resulted in recovering of apoptosis by complete down-regulation of the antiapoptotic proteins Bcl-2 and Mcl-1. Cooperation between BRAF and MEK inhibitors has also been demonstrated in preclinical studies with a consistent increase of apoptosis and abroga‐ tion of ERK activation compared to BRAF inhibitor alone [130]. Such cooperation was based on the observation that MEK activation was not abrogated in melanoma cells that develop resistance to BRAF inhibitors [131-134]. BRAF and MEK targeted synergic therapy is cur‐ rently tested in a phase I clinical trial (NCT01072175) which combines the selective RAF in‐ hibitor GSK2118436 with the MEK inhibitor GSK1120212 in patients with BRAF mutant tumors [135].

After decades without perspective, the history of medical treatment for the advanced mela‐ noma is rapidly changing. Combined therapeutic approaches do represent the next chal‐ lenge for treatment of patients with such a disease.

## **Acknowledgments**

Authors are always grateful to patients for their cooperation into the various studies. Work was funded by Regione Autonoma della Sardegna and Ricerca Finalizzata Ministero della Salute.

## **Author details**

**Figure 3. Principal genetic and molecular tests on tumor tissues for the different types of melanoma.** Amp, gene amplification detected by *fluorescence in situ hybridization* (FISH) analysis. Exp, protein expression level detected by immunohistochemistry. Mut, gene sequence variation detected by mutation analysis. In red, tests for less prevalent

Taken together all the described molecular mechanisms involved in melanoma genesis and progression, data seem to emphasize the fact that in melanoma, but probably in all types of cancer, it is unlikely that targeting a single component in the signalling pathway will yield significant anti-tumour responses. For this purpose, molecular analyses could help clinicians to define the prognosis (prognostic value) as well as to make a prediction, identifying the subsets of patients who would be expected to be more or less likely to respond to specific

In other words, it is becoming evident that combination therapies targeting simultaneously several signaling pathways might be a winning therapeutic strategy to treat melanoma pa‐ tients. Preclinical studies using combination of anti BRAF and AKT3 siRNA demonstrated a significantly higher reduction of tumor growth compared to single agent administration [126-127]. There is also evidence of synergism among MEK and PI3K inhibitors as well as promising results have been obtained by combinations of the mTOR inhibitors and sorafe‐ nib or MEK inhibitors [121, 128-129]. In contrast to single agent activity, these combinations of target drugs resulted in recovering of apoptosis by complete down-regulation of the antiapoptotic proteins Bcl-2 and Mcl-1. Cooperation between BRAF and MEK inhibitors has also been demonstrated in preclinical studies with a consistent increase of apoptosis and abroga‐ tion of ERK activation compared to BRAF inhibitor alone [130]. Such cooperation was based on the observation that MEK activation was not abrogated in melanoma cells that develop

alterations.

**5. Conclusion**

46 Melanoma - From Early Detection to Treatment

therapeutic interventions (predictive value).

Giuseppe Palmieri1\*, Maria Colombino1 , Maria Cristina Sini1 , Paolo Antonio Ascierto2 , Amelia Lissia3 and Antonio Cossu3

\*Address all correspondence to<EMAIL_ADDRESS>
1 Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Traversa La Crucca, 3 - Baldinca Li Punti, Sassari, Italy

2 Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione "G. Pascale", Via Mariano Semmola, Napoli, Italy

3 University Hospital Health Unit - Azienda Ospedaliero Universitaria (AOU), Via Matteot‐ ti, Sassari, Italy

## **References**

[4] Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005: 331: 481;

[20] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

49

PA. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-54

noma? Int J Cancer 2003; 104:527-32

cer Metastasis Reviews 24: 195–222, 2005

nevi. Nat Genet. 2003, 33:19-20

2008;132:363–374

[21] Smalley KSM. A pivotal role for ERK in the oncogenic behaviour of malignant mela‐

[22] McGary EC, Chelouche Lev D, Bar-Eli M. Cellular adhesion pathways and metastatic

[23] Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Can‐

[24] Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallio‐ niemi O, Hayward NK, Trent JM, Meltzer PS. High frequency of BRAF mutations in

[25] Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-

[26] Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Bergh‐ mans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI. BRAF mutations are sufficient to promote nevi formation and co‐

[27] Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell.

[28] Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte

[29] Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. Increased cy‐ clin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated

[30] Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajew‐ ski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future Perspectives in

operate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249–54

senescence and melanoma in mice. Cancer Cell. 2009;15:294–303

melanomas. Mol Cancer Ther. 2008; 7: 2876-83

potential of human melanoma. Cancer Biol Ther 2002; 5: 459-465

like cell cycle arrest of human naevi. Nature 2005; 436, 720–724

[20] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-54

[4] Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma:

[5] de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. BMJ. 2005: 331:

[6] Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant

[7] Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. The Lancet 2005: 365:

[8] Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities

[9] Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Ger‐ shenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J

[10] Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based

[11] Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in sig‐

[12] Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in

[13] Palmieri G, Capone ME, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Transl Med. 2009; 7: 86

[15] Giehl K. Oncogenic Ras in tumor progression and metastasis. Biol Chem.

[16] Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS co‐ operate to drive tumor progression through CRAF. Cell. 2010 Jan 22;140:209-21

[17] Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature.

[18] Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer.

[19] Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS co‐ operate to drive tumor progression through CRAF. Cell. 2010; 140:209-21

population based ecological study. BMJ 2005: 331: 481;

of melanoma for whites. J Clin Oncol. 2005: 23: 2669-2675

on DNA copy number changes. Am J Pathol 2003;163:1765-70

naling pathways in melanoma. Clin Cancer Res. 2006; 12: 2301-7

[14] Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355, 51-65

melanoma. N Engl J Med. 2005; 353:2135-47

melanoma. Oncogene 2003: 22: 3099-3112

Clin Oncol 2001; 19: 3635-48

2005;386:193–205

2002;418:934

Future Oncol. 2009; 5:105-16

698

48 Melanoma - From Early Detection to Treatment

687-701

melanoma research. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J. Transl Med. 10: 83, 2012

[44] Hauser JE, Kadekaro AL, Kavanagh RJ, et al. Melanin content and MC1R function in‐ dependently affect UVR-induced DNA damage in cultured human melanocytes. Pig‐

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

51

[45] Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-

[46] Fargnoli MC, Pike K, Pfeiffer RM, et al. MC1R variants increase risk of melanomas

[47] Thomas NE, Kanetsky PA, Edmiston SN, et al. Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. J

[48] Scherer D, Rachakonda PS, Angelini S, et al. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. J Invest Derma‐

[49] Hacker E, Hayward NK, Dumenil T, et al. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian pop‐

[50] Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene.

[51] Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human

[52] Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than

[53] Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Klug‐ er HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Can‐

[54] Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the

[55] Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of muta‐ tions in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol.

[56] Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122: 337–41

[57] Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Berou‐ khim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;

harboring BRAF mutations. J Invest Dermatol. 2008; 128:2485-90

ment Cell Res. 2006; 19:303-14

Invest Dermatol. 2010; 130:1463-5

ulation.J Invest Dermatol. 2010; 130:241-8

cancer. Nat Rev Cancer. 2002;2:489-501

just surviving. Oncogene. 2005;24:7435–7442

PTEN gene in melanoma. Cancer Res. 2006; 66: 6546-52

tol. 2010; 130:2844-8

2003; 22: 3113-22

cer Res. 2009; 15: 3029-36

2006; 126:154-60

436:117-22.

mutant melanoma. Science 2006; 313:521-2

[44] Hauser JE, Kadekaro AL, Kavanagh RJ, et al. Melanin content and MC1R function in‐ dependently affect UVR-induced DNA damage in cultured human melanocytes. Pig‐ ment Cell Res. 2006; 19:303-14

melanoma research. Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J. Transl Med. 10: 83, 2012

[31] Pomerantz J, Schreiber-Agus N, Lie´ geois NJ. The Ink4a tumor suppressor gene product, 19Arf, interacts with MDM2 and neutralizes DM2's inhibition of p53. Cell

[32] Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression path‐

[33] Palmieri G, Capone ME, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Transl Med. 7: 86, 2009

[34] Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Bénard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study

[35] Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous

[36] Box NF, Terzian T: The role of p53 in pigmentation, tanning and melanoma. Pigment

[37] Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol. 2008;

[38] Bennett DC. How to make a melanoma: what do we know of the primary clonal

[39] Sini MC, Manca A, Cossu A, Budroni M, Botti G, Ascierto PA, Cremona F, Muggiano A, D'Atri S, Casula M, Baldinu P, Palomba G, Lissia A, Tanda F, Palmieri G. Molecu‐ lar alterations at chromosome 9p21 in melanocytic nevi and melanoma. Br. J. Derma‐

[40] Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet. 2009; 126:

[41] Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variants in‐ crease melanoma risk in famiglie with CDKN2A mutations: A meta-analysis. Eur J

[42] Scott MC, Wakamatsu K, Ito S, et al. Human melanocortin 1 receptor variants, recep‐ tor function and melanocyte response to UV radiation. J Cell Sci. 2002; 115: 2349-55

[43] Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development

and melanoma oncogene. Trends Mol. Med. 2006;12, 406–414

1998; 92: 713-23

50 Melanoma - From Early Detection to Treatment

128:2575-95

499-510

tology 158: 243-250, 2008

Cancer 2010; 46: 1413-20

ways. Cell 1998: 92: 725–734

Group. Hum Mol Genet. 1998; 7: 209-16

melanoma. Cancer Res. 2002; 62:3200-6

Cell Melanoma Res 2008, 21:525-533

events? Pigment Cell Melanoma Res. 2008; 21:27-38

[58] Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433: 764-769

[71] Dhawan P, Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 2002;

Targeted Therapies in Melanoma: Successes and Pitfalls

http://dx.doi.org/10.5772/53624

53

[72] Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol.

[73] Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcrip‐

[74] Madonna G, Dansky Ullman C, Gentilcore G, Palmieri G, Ascierto PA. NF-kappaB as

[75] Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 2011; 30:1615-30.

[76] Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer.

[77] McNulty SE, del Rosario R, Cen D, et al. Comparative expression of NFkappaB pro‐ teins in melanocytes of normal skin vs. benign intradermal naevus and human meta‐

[78] Clifford D, Mol, Kheng B. Lim. Structure of a c-Kit product complex reveals the basis

[79] Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in

[80] Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in

[81] Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression

[82] Stefanou D, Batistatou A, Zioga A. Immunohistochemical expression of vascular en‐ dothelial growth factor (VEGF) and CKIT in cutaneous melanocytic lesions. Int J

[83] Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct sub‐

[84] Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Har‐ low A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. Kit gene mutations and copy numbering melanoma subtypes .Clin Cancer Res 2008; 14:

[85] Riviera RS, Nagatsuka H, Gunduz M, Cengiz B, Gunduz E, Siar CH, Tsujigiwa H, Tamamura R, Han K N, Nagai N. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma.Virchows Arch. 2008; 452: 27-32

static melanoma biopsies. Pigment Cell Res. 2004; 17:173-80

for kinase transactivation. J. Biol Chem 2003; 278: 31461-64

types of melanoma. J. Clin. Oncol. 2006; 24: 4340-43

sub-groups of melanomas. Histol Histopathol. 2009; 24:643-50.

mammalian melanocytes. J Invest Dermatol. 2006; 126: 1102-1110

in melanocytic lesions by tissue array. J Cutan Pathol 2003; 30: 539-547

potential target in the treatment of melanoma. J. Transl Med. 2012; 10: 53

tion factor NF-kB. J Clin Invest 2001;107:241–246

Cell Death Differ. 2006; 13:738-47

Surg Pathol 2004; 12: 133-138.

6821-6828

277:7920-8

2009; 129:148-54

[71] Dhawan P, Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 2002; 277:7920-8